UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-Q
(Mark
One)
x
|
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
FOR
THE
QUARTERLY PERIOD ENDED MARCH 31, 2007
OR
¨
|
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
FOR
THE
TRANSITION PERIOD FROM _________TO _________
COMMISSION
FILE NUMBER
PATIENT
SAFETY TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
13-3419202
|
(State
or other jurisdiction of incorporation or
organization)
|
|
(I.R.S.
Employer Identification Number)
|
|
|
|
27555
Ynez Road, Suite 330, Temecula, CA 92591
|
(Address
of principal executive offices) (Zip
Code)
|
Registrant’s
telephone number, including area code: (951)
587-6201
Indicate
by check mark whether the registrant (1) has filed all reports required to
be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the
past 12 months (or for such shorter period that the registrant was required
to
file such reports), and (2) has been subject to such filing requirements for
the
past 90 days. Yes
x No ¨.
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of “accelerated
filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check
one):
Large
accelerated filer ¨
|
Accelerated
filer ¨
|
Non-accelerated
filer x
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2) of the Act. Yes ¨ No x.
There
were 9,937,059 shares of the registrant's common stock outstanding as of May
8,
2007.
PATIENT
SAFETY TECHNOLOGIES, INC.
FORM
10-Q FOR THE QUARTER
ENDED
MARCH 31, 2007
TABLE
OF CONTENTS
|
Page
|
PART
I - FINANCIAL INFORMATION
|
|
|
Item
1. Financial Statements
|
1
|
Item
2. Management’s Discussion and Analysis of Financial Condition and Results
of Operations
|
17
|
Item
3. Quantitative and Qualitative Disclosures About Market
Risk
|
29
|
Item
4. Controls and Procedures
|
29
|
|
|
PART
II - OTHER INFORMATION
|
|
|
Item
1. Legal Proceedings
|
29
|
Item
1A. Risk Factors
|
29
|
Item
2. Unregistered Sales of Equity Securities and Use of
Proceeds
|
29
|
Item
3. Defaults Upon Senior Securities
|
31
|
Item
4. Submission of Matters to a Vote of Security Holders
|
31
|
Item
5. Other Information
|
31
|
Item
6. Exhibits
|
31
|
|
|
SIGNATURES
|
32
|
"SAFE
HARBOR" STATEMENT UNDER
THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
We
believe that it is important to communicate our plans and expectations about
the
future to our stockholders and to the public. Some of the statements in this
report are forward-looking statements about our plans and expectations of what
may happen in the future, including in particular the statements about our
plans
and expectations in Part I of this report under the heading “Item 2.
Management's Discussion and Analysis of Financial Condition and Results of
Operations.” Statements that are not historical facts are forward-looking
statements. These forward-looking statements are made pursuant to the
“safe-harbor” provisions of the Private Securities Litigation Reform Act of
1995. You can sometimes identify forward-looking statements by our use of
forward-looking words like “may,” “should,” “expects,” “intends,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue”
or the negative of these terms and other similar expressions.
Although
we believe that the plans and expectations reflected in or suggested by our
forward-looking statements are reasonable, those statements are based only
on
the current beliefs and assumptions of our management and on information
currently available to us and, therefore, they involve uncertainties and risks
as to what may happen in the future. Accordingly, we cannot guarantee you that
our plans and expectations will be achieved. Our actual results and stockholder
values could be very different from and worse than those expressed in or implied
by any forward-looking statement in this report as a result of many known and
unknown factors, many of which are beyond our ability to predict or control.
These factors include, but are not limited to, those contained in Part II of
this report under “Item 1A. Risk Factors.” All written and oral forward-looking
statements attributable to us are expressly qualified in their entirety by
these
cautionary statements.
Our
forward-looking statements speak only as of the date they are made and should
not be relied upon as representing our plans and expectations as of any
subsequent date. Although we may elect to update or revise forward-looking
statements at some time in the future, we specifically disclaim any obligation
to do so, even if our plans and expectations change.
PART
I - FINANCIAL INFORMATION
Item
1. Financial Statements.
PATIENT
SAFETY TECHNOLOGIES, INC. AND SUBSIDIARIES
|
|
Consolidated
Balance Sheets (Unaudited)
|
|
|
March
31,
|
|
December
31,
|
|
|
|
2007
|
|
2006
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
1,410,705
|
|
$
|
3,775
|
|
Accounts
receivable
|
|
|
198,648
|
|
|
65,933
|
|
Inventories
|
|
|
42,825
|
|
|
42,825
|
|
Prepaid
expenses
|
|
|
437,640
|
|
|
78,834
|
|
Other
current assets
|
|
|
16,620
|
|
|
13,125
|
|
|
|
|
|
|
|
|
|
TOTAL
CURRENT ASSETS
|
|
|
2,106,438
|
|
|
204,492
|
|
|
|
|
|
|
|
|
|
Restricted
certificate of deposit
|
|
|
87,500
|
|
|
87,500
|
|
Notes
receivable
|
|
|
153,668
|
|
|
153,668
|
|
Property
and equipment, net
|
|
|
375,308
|
|
|
328,202
|
|
Assets
held for sale, net
|
|
|
3,178,765
|
|
|
3,189,674
|
|
Goodwill
|
|
|
1,687,527
|
|
|
1,687,527
|
|
Patents,
net
|
|
|
4,007,615
|
|
|
4,088,850
|
|
Long-term
investments
|
|
|
1,441,533
|
|
|
1,441,533
|
|
|
|
|
|
|
|
|
|
TOTAL
ASSETS
|
|
$
|
13,038,354
|
|
$
|
11,181,446
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes
payable, current portion - net
|
|
$
|
4,279,138
|
|
$
|
3,517,149
|
|
Accounts
payable
|
|
|
1,083,540
|
|
|
1,295,849
|
|
Accrued
liabilities
|
|
|
928,974
|
|
|
824,466
|
|
|
|
|
|
|
|
|
|
TOTAL
CURRENT LIABILITIES
|
|
|
6,291,652
|
|
|
5,637,464
|
|
|
|
|
|
|
|
|
|
Notes
payable, less current portion - net
|
|
|
1,495,000
|
|
|
2,527,562
|
|
Deferred
tax liabilities
|
|
|
1,443,821
|
|
|
1,473,066
|
|
|
|
|
|
|
|
|
|
COMMITMENTS
AND CONTINGENCIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS'
EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible
preferred stock, $1.00 par value, cumulative 7% dividend:
|
|
|
|
|
|
|
|
1,000,000
shares authorized; 10,950 issued and outstanding
|
|
|
|
|
|
|
|
at
March 31, 2007 and December 31, 2006
|
|
|
|
|
|
|
|
(Liquidation
preference of $1,229,139 at March 31, 2007 and $1,209,976 at
December
31, 2006, respectively)
|
|
|
10,950
|
|
|
10,950
|
|
Common
stock, $0.33 par value: 25,000,000 shares authorized;
|
|
|
|
|
|
|
|
9,832,200
shares issued and outstanding as of March 31, 2007;
7,489,026
|
|
|
|
|
|
|
|
shares
issued and 6,874,889 shares outstanding at December 31,
2006
|
|
|
3,244,626
|
|
|
2,471,379
|
|
Additional
paid-in capital
|
|
|
31,480,431
|
|
|
29,654,341
|
|
Accumulated
deficit
|
|
|
(30,928,126
|
)
|
|
(29,483,910
|
)
|
|
|
|
|
|
|
|
|
|
|
|
3,807,881
|
|
|
2,652,760
|
|
|
|
|
|
|
|
|
|
Less:
614,137 shares of treasury stock, at cost, at December 31,
2006
|
|
|
—
|
|
|
(1,109,406
|
)
|
|
|
|
|
|
|
|
|
TOTAL
STOCKHOLDERS' EQUITY
|
|
|
3,807,881
|
|
|
1,543,354
|
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
$
|
13,038,354
|
|
$
|
11,181,446
|
|
The
accompanying notes are an integral part of these consolidated interim financial
statements.
PATIENT
SAFETY TECHNOLOGIES, INC. AND SUBSIDIARIES
|
|
Consolidated
Statements of Operations and Comprehensive Loss
(Unaudited)
|
|
|
For
The Three Months Ended March 31,
|
|
|
|
2007
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REVENUES
|
|
$
|
307,158
|
|
$
|
54,993
|
|
|
|
|
|
|
|
|
|
OPERATING
EXPENSES
|
|
|
|
|
|
|
|
Cost
of sales
|
|
|
214,210
|
|
|
—
|
|
Salaries
and employee benefits
|
|
|
498,280
|
|
|
2,385,250
|
|
Professional
fees
|
|
|
303,473
|
|
|
612,307
|
|
Rent
|
|
|
38,582
|
|
|
33,287
|
|
Insurance
|
|
|
42,772
|
|
|
27,359
|
|
Taxes
other than income taxes
|
|
|
27,158
|
|
|
31,245
|
|
Amortization
of patents
|
|
|
81,235
|
|
|
81,235
|
|
General
and administrative
|
|
|
203,682
|
|
|
223,939
|
|
|
|
|
|
|
|
|
|
Total
operating expenses
|
|
|
1,409,392
|
|
|
3,394,622
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(1,102,234
|
)
|
|
(3,339,629
|
)
|
|
|
|
|
|
|
|
|
OTHER
INCOME (EXPENSES)
|
|
|
|
|
|
|
|
Interest,
dividend income and other
|
|
|
4,287
|
|
|
1,094
|
|
Realized
(loss) on investments, net
|
|
|
—
|
|
|
(136,262
|
)
|
Interest
expense
|
|
|
(267,584
|
)
|
|
(34,683
|
)
|
Unrealized
gain on marketable securities, net
|
|
|
—
|
|
|
76,915
|
|
|
|
|
|
|
|
|
|
Loss
from continuing operations before income taxes
|
|
|
(1,365,531
|
)
|
|
(3,432,565
|
)
|
|
|
|
|
|
|
|
|
Income
tax benefit
|
|
|
29,245
|
|
|
29,245
|
|
|
|
|
|
|
|
|
|
Loss
from continuing operations
|
|
|
(1,336,286
|
)
|
|
(3,403,320
|
)
|
|
|
|
|
|
|
|
|
Loss
from discontinued operations
|
|
|
(88,767
|
)
|
|
(170,212
|
)
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
(1,425,053
|
)
|
|
(3,573,532
|
)
|
|
|
|
|
|
|
|
|
Preferred
dividends
|
|
|
(19,163
|
)
|
|
(19,163
|
)
|
|
|
|
|
|
|
|
|
Loss
available to common shareholders
|
|
$
|
(1,444,216
|
)
|
$
|
(3,592,695
|
)
|
|
|
|
|
|
|
|
|
Basic
and diluted net loss per common share
|
|
|
|
|
|
|
|
Continuing
operations
|
|
$
|
(0.17
|
)
|
$
|
(0.57
|
)
|
Discontinued
operations
|
|
$
|
(0.01
|
)
|
$
|
(0.03
|
)
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(0.18
|
)
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
Weighted
average common shares outstanding - basic and
diluted
|
|
|
7,789,581
|
|
|
6,003,103
|
|
|
|
|
|
|
|
|
|
Comprehensive
loss:
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(1,425,053
|
)
|
$
|
(3,573,532
|
)
|
Other
comprehensive (loss), unrealized (loss) on available-for-sale
investments
|
|
|
—
|
|
|
(745,715
|
)
|
|
|
|
|
|
|
|
|
Total
comprehensive loss
|
|
$
|
(1,425,053
|
)
|
$
|
(4,319,247
|
)
|
The
accompanying notes are an integral part of these consolidated interim financial
statements.
PATIENT
SAFETY TECHNOLOGIES, INC. AND SUBSIDIARIES
|
|
Consolidated
Statements of Cash Flows
(Unaudited)
|
|
|
For
The Three Months Ended March 31,
|
|
|
|
2007
|
|
2006
|
|
Cash
flows from operating activities:
|
|
|
|
|
|
Net
loss
|
|
$
|
(1,425,053
|
)
|
$
|
(3,573,532
|
)
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
Depreciation
|
|
|
31,911
|
|
|
8,519
|
|
Amortization
of patents
|
|
|
81,235
|
|
|
81,235
|
|
Non-cash
interest
|
|
|
169,427
|
|
|
75,245
|
|
Realized loss
on investments, net
|
|
|
—
|
|
|
136,262
|
|
Unrealized
gain on marketable securities
|
|
|
—
|
|
|
(76,915
|
)
|
Stock-based
compensation to employees and directors
|
|
|
249,900
|
|
|
1,935,967
|
|
Stock-based
compensation to consultants
|
|
|
61,703
|
|
|
418,012
|
|
Income
tax benefit
|
|
|
(29,245
|
)
|
|
(29,245
|
)
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(132,715
|
)
|
|
900,000
|
|
Marketable
securities, net
|
|
|
—
|
|
|
749,544
|
|
Prepaid
expenses
|
|
|
141,194
|
|
|
(17,873
|
)
|
Other
current assets
|
|
|
(3,495
|
)
|
|
(66
|
)
|
Assets
held for sale, net
|
|
|
10,909
|
|
|
—
|
|
Accounts
payable
|
|
|
(212,309
|
)
|
|
(241,702
|
)
|
Accrued
liabilities
|
|
|
85,345
|
|
|
167,935
|
|
Due
to broker
|
|
|
—
|
|
|
(526,807
|
)
|
|
|
|
|
|
|
|
|
Net
cash (used in) provided by operating activities
|
|
|
(971,193
|
)
|
|
6,579
|
|
|
|
|
|
|
|
|
|
Cash
flows from investing activities:
|
|
|
|
|
|
|
|
Purchase
of property and equipment
|
|
|
(79,017
|
)
|
|
(2,102,853
|
)
|
Proceeds
from sale of long-term investments
|
|
|
—
|
|
|
20,508
|
|
|
|
|
|
|
|
|
|
Net
cash used in investing activities
|
|
|
(79,017
|
)
|
|
(2,082,345
|
)
|
|
|
|
|
|
|
|
|
Cash
flows from financing activities:
|
|
|
|
|
|
|
|
Proceeds
from issuance of common stock and warrants
|
|
|
2,897,140
|
|
|
—
|
|
Proceeds
from notes payable
|
|
|
10,000
|
|
|
2,685,893
|
|
Payments
and decrease on notes payable
|
|
|
(450,000
|
)
|
|
(631,637
|
)
|
|
|
|
|
|
|
|
|
Net
cash provided by financing activities
|
|
|
2,457,140
|
|
|
2,054,256
|
|
|
|
|
|
|
|
|
|
Net increase
(decrease) in cash
|
|
|
1,406,930
|
|
|
(21,510
|
)
|
|
|
|
|
|
|
|
|
Cash
at beginning of period
|
|
|
3,775
|
|
|
79,373
|
|
|
|
|
|
|
|
|
|
Cash
at end of period
|
|
$
|
1,410,705
|
|
$
|
57,863
|
|
The
accompanying notes are an integral part of these consolidated interim financial
statements.
PATIENT
SAFETY TECHNOLOGIES, INC. AND SUBSIDIARIES
|
|
Consolidated
Statements of Cash Flows
(continued)
|
|
|
For
The Three Months Ended March 31,
|
|
|
|
2007
|
|
2006
|
|
|
|
|
|
|
|
Supplemental
disclosures of cash flow information:
|
|
|
|
|
|
Cash
paid during the period for interest
|
|
$
|
963
|
|
$
|
12,946
|
|
|
|
|
|
|
|
|
|
Supplemental
schedule of non cash investing and financing activities:
|
|
|
|
|
|
|
|
Dividends
accrued
|
|
$
|
19,163
|
|
$
|
19,163
|
|
Capitalized
interest
|
|
$
|
—
|
|
$
|
30,453
|
|
Insuance
of common stock for prepayment of inventory |
|
$
|
500,000 |
|
$
|
—
|
|
|
|
|
|
|
|
|
|
Purchase
of the remaining 50% interest in ASG, through issuance of common
stock,
resulting in the following asset acquired and liabilities assumed
during
the quarter ended March 31, 2006 as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ASG
|
|
Goodwill
|
|
|
|
|
$
|
357,008
|
|
Common
stock issued
|
|
|
|
|
$
|
(610,000
|
)
|
Minority
interest
|
|
|
|
|
$
|
252,992
|
|
Liabilities
assumed
|
|
|
|
|
$
|
—
|
|
The
accompanying notes are an integral part of these consolidated interim financial
statements.
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
March
31, 2007
1.
DESCRIPTION OF BUSINESS
Patient
Safety Technologies, Inc. ("PST"
or the
"Company")
is a
Delaware corporation. Until March 31, 2005, the Company was a Business
Development Company (“BDC”)
under
the Investment Company Act of 1940, as amended. On March 30, 2005, stockholder
approval was obtained to withdraw the Company’s election to be treated as a BDC
and on March 31, 2005, the Company filed an election to withdraw its election
with the Securities and Exchange Commission (“SEC”).
The
Company currently has two wholly-owned operating subsidiaries: Surgicount
Medical, Inc. (“Surgicount”),
a
California corporation; and Automotive Services Group, Inc., (formerly known
as
Ault Glazer Bodnar Merchant Capital, Inc.) a Delaware corporation.
The
Company’s primary focus is development, manufacturing and distribution of
products and services focused primarily in the health care and medical products
field, particularly the patient safety markets. Surgicount is a developer and
manufacturer of patient safety products and services. The SurgiCount
Safety-SpongeTM
System
is
a patented turn-key array of modified surgical sponges, line-of-sight scanning
SurgiCounters, and printPAD printers integrated together to form a comprehensive
counting and documentation system.
The
Company also operates a car wash through Automotive Services Group, Inc.
(“Automotive
Services Group”),
which
holds the Company’s investment in Automotive Services Group, LLC (“ASG”),
its
wholly-owned subsidiary. As discussed in Note 4, during the fourth quarter
of
2006 the Company began marketing the assets held in ASG for sale. In addition,
the Company holds various other unrelated investments including investments
in
real estate and in a financial services company, which it is in the process
of
liquidating as part of a strategic plan adopted during 2006 to dispose of all
of
the Company’s non patient safety related assets.
2.
LIQUIDITY AND GOING CONCERN
The
accompanying unaudited consolidated interim financial statements have been
prepared assuming that the Company will continue as a going concern. At March
31, 2007, the Company has an accumulated deficit of approximately $30.9 million
and a working capital deficit of approximately $4.2 million. For the three
months ended March 31, 2007, the Company incurred a loss of approximately $1.4
million and has utilized approximately $1.0 million in cash in its operations.
Further, as of March 31, 2007, the Company has only generated minimal revenues
from its medical products and healthcare solutions segments. These conditions
raise substantial doubt about the Company’s ability to continue as a going
concern. The Company has relied on liquidating investments and short-term debt
financings to fund a large portion of its operations. In order to ensure the
continued viability of the Company, equity financing and profitable operations
must be obtained in order to repay the existing short-term debt and to provide
a
sufficient source of operating capital. Although the Company has received equity
financing during the three months ended March 31, 2007, the Company is currently
seeking additional financing and believes that it will be successful. However,
no assurances can be made that it will be successful obtaining a sufficient
amount of equity financing to continue to fund its operations or that the
Company will achieve profitable operations and positive cash flow from its
medical products segment. The consolidated financial statements do not include
any adjustments that might result from the outcome of this
uncertainty.
3.
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation
The
accompanying unaudited consolidated interim financial statements have been
prepared in accordance with the instructions to Form 10-Q and Article 10 of
Regulation S-X and do not include all the information and disclosures required
by accounting principles generally accepted in the United States of America.
The
consolidated interim financial information is unaudited, but reflects all normal
adjustments that are, in the opinion of management, necessary to provide a
fair
statement of results for the interim periods presented. The consolidated balance
sheet as of December 31, 2006 was derived from the Company’s audited financial
statements. The consolidated interim financial statements should be read in
conjunction with the consolidated financial statements in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2006. Results of the three
months ended March 31, 2007 are not necessarily indicative of the results to
be
expected for the full year ending December 31, 2007. All intercompany
transactions have been eliminated in consolidation.
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
Revenue
Recognition
The
Company complies with SEC Staff Accounting Bulletin (“SAB”)
101,
Revenue
Recognition in Financial Statements,
amended
by SAB 104, Revenue
Recognition.
Consulting service contract revenue is recognized when the service is performed.
Consequently, the recognition of such consulting service contract revenue is
deferred until each phase of the contract is complete. Revenues generated by
the
Company’s automated car wash subsidiary, Automotive Services Group are
recognized at the time of service. Revenues from sales of the
Safety-SpongeTM
System
are recorded upon shipment.
Goodwill
and Intangible Assets
Long-Lived
Assets
The
Company evaluates long-lived assets for impairment in accordance with SFAS
No. 144, Accounting
for the Impairment or Disposal of Long-Lived Assets, which
requires impairment evaluation on long-lived assets used in operations when
indicators of impairment are present. Reviews are performed to determine
whether the carrying value of assets is impaired, based on a comparison to
undiscounted expected future cash flows. If this comparison indicates that
there is impairment, the impaired asset is written down to fair value, which
is
typically calculated using discounted expected future cash flows and a discount
rate based upon the Company’s weighted average cost of capital adjusted for
risks associated with the related operations. Impairment is based on the
excess of the carrying amount over the fair value of those assets.
Stock-Based
Compensation
The
Company adopted SFAS No. 123(R), Share-Based
Payment,
as of
January 1, 2005 using the modified retrospective application method as provided
by SFAS 123(R) and accordingly, financial statement amounts for the prior
periods in which the Company granted employee stock options have been restated
to reflect the fair value method of expensing prescribed by SFAS 123(R). During
the three months ended March 31, 2007 and 2006, the Company had stock-based
compensation expense of $250,000 and $1,936,000, respectively, related to
issuances to the Company’s employee and directors, included in reported net
losses for these periods. The total amount of stock-based compensation for
the
three months ended March 31, 2007 of $250,000 included expenses related to
restricted stock grants valued at $192,000 and stock options valued at $58,000.
The total amount of stock based compensation for the three months ended March
31, 2006 of $1,936,000 included expenses related to restricted stock grants
valued at $1,014,000 and stock options valued at $922,000.
During
the three months ended March 31, 2007 and 2006, the Company had stock-based
compensation expense, from issuances of restricted stock and warrants to
consultants of the Company of $62,000 and $418,000, respectively.
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
A
summary
of stock option activity for the three months ended March 31,
2007 is presented below:
|
|
|
|
Outstanding
Options
|
|
|
|
Shares
Available for Grant
|
|
Number
of Shares
|
|
Weighted
Average Exercise Price
|
|
Weighted
Average Remaining Contractual Life (years)
|
|
Aggregate
Intrinsic Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2006
|
|
|
26,026
|
|
|
1,704,000
|
|
$
|
4.50
|
|
|
8.73
|
|
|
|
|
Restricted
Stock Awards
|
|
|
(79,032
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Grants
|
|
|
(75,000
|
)
|
|
75,000
|
|
$
|
1.60
|
|
|
9.91
|
|
|
|
|
Cancellations
|
|
|
189,000
|
|
|
(189,000
|
)
|
$
|
5.11
|
|
|
8.26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March
31, 2007
|
|
|
60,994
|
|
|
1,590,000
|
|
$
|
4.23
|
|
|
8.35
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options
exercisable at:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2006
|
|
|
|
|
|
832,625
|
|
$
|
4.90
|
|
|
8.54
|
|
$
|
—
|
|
March
31, 2007
|
|
|
|
|
|
719,375
|
|
$
|
4.89
|
|
|
8.12
|
|
$
|
—
|
|
The
aggregate intrinsic value in the table above represents the total pretax
intrinsic value (i.e., the difference between our closing stock price on March
31, 2007 and the exercise price, times the number of shares) that would have
been received by the option holders had all option holders exercised their
options on March 31, 2007. There have not been any options exercised during
the
three months ended March 31, 2007.
All
options that the Company granted during the three months ended March 31, 2007
and 2006 were granted at the per share fair market value on the grant date.
Vesting of options differs based on the terms of each option. The Company
utilized the Black-Scholes option pricing model and the assumptions used for
each period are as follows:
|
|
Three
Months ended March 31,
|
|
|
|
2007
|
|
2006
|
|
Weighted
average risk free interest rate
|
|
|
4.50
|
%
|
|
3.75
|
%
|
Weighted
average life (in years)
|
|
|
5.00
|
|
|
3.0
|
|
Volatility
|
|
|
100
|
%
|
|
89
|
%
|
Expected
dividend yield
|
|
|
0
|
%
|
|
0
|
%
|
Weighted
average grant-date fair value per share of options granted
|
|
$
|
1.22
|
|
$
|
2.51
|
|
As
of
March 31, 2007, total unrecognized compensation cost related to unvested stock
options was $975,000. The cost is expected to be recognized over a weighted
average period of 1.51 years.
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
Beneficial
Conversion Feature of Convertible Notes Payable
The
convertible feature of certain notes payable provides for a rate of conversion
that is below market value. Such feature is normally characterized as a
Beneficial Conversion Feature (“BCF”).
Pursuant to EITF Issue No. 98-5, Accounting
for Convertible Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratio,
EITF No.
00-27, Application
of EITF Issue No. 98-5 To Certain Convertible Instruments
and APB
14, Accounting
for Convertible Debt and Debt Issued with Stock Purchase
Warrants,
the
estimated fair value of the BCF is recorded in the consolidated financial
statements as a discount from the face amount of the notes. Such discounts
are
amortized to accretion of convertible debt discount over the term of the notes
(or conversion of the notes, if sooner).
Earnings
per Common Share
Loss
per
common share is based on the weighted average number of common shares
outstanding. The Company complies with SFAS No. 128, Earnings
Per Share,
which
requires dual presentation of basic and diluted earnings per share on the face
of the consolidated statements of operations. Basic loss per common share
excludes dilution and is computed by dividing income (loss) available to common
stockholders by the weighted-average common shares outstanding for the period.
Diluted loss per common share reflects the potential dilution that could occur
if convertible preferred stock or debentures, options and warrants were to
be
exercised or converted or otherwise resulted in the issuance of common stock
that then shared in the earnings of the entity.
Since
the
effects of outstanding options, warrants and the conversion of convertible
preferred stock and convertible debt are anti-dilutive in all periods presented,
shares of common stock underlying these instruments have been excluded from
the
computation of loss per common share.
Use
of Estimates
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. The actual results may differ from
management’s estimates.
Recent
Accounting Pronouncements
In
June 2006, the FASB issued
FASB Interpretation Number 48 (“FIN
48”),
Accounting
for Uncertainty in Income Taxes—an interpretation of FASB Statement
No. 109.
FIN 48
prescribes a recognition threshold and measurement attribute for the financial
statement recognition and measurement of a tax position that an entity takes
or
expects to take in a tax return. Additionally, FIN 48 provides guidance on
de-recognition, classification, interest and penalties, accounting in interim
periods, disclosure, and transition. Under FIN 48, an entity may only
recognize or continue to recognize tax positions that meet a “more likely than
not” threshold. FIN 48 was effective
for the Company beginning January 1, 2007. In
connection with the adoption of FIN 48, no liability for unrecognized income
tax
benefits was recorded and no interest and penalties related to uncertain tax
positions was recognized. The tax years 2003 -2006 remain open to examination
by
the major taxing jurisdictions.
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
4.
DISCONTINUED OPERATIONS
As
part
of a strategic plan to dispose of all the Company’s non-patient safety related
assets, during the fourth quarter of 2006, the Company began marketing for
sale the assets of Automotive
Services Group,
located
in Alabama. The Company anticipates operating and generating operating cash
flow
from the one operating car wash until its disposition. The assets of
Automotive
Services Group
met the
“held for sale” and “discontinued operations” criteria in accordance with SFAS
144.
The
following sets forth the discontinued operations for the three months ended
March 31, 2007 and 2006 related to the held for sale assets of
Automotive Services Group:
|
|
Three
Months Ended March 31,
|
|
|
|
2007
|
|
2006
|
|
Operating
revenues
|
|
$
|
159,864
|
|
$
|
20,767
|
|
Operating
expenses
|
|
|
134,929
|
|
|
93,259
|
|
Depreciation
and amortization
|
|
|
10,909
|
|
|
—
|
|
Interest
expense
|
|
|
102,793
|
|
|
97,720
|
|
|
|
|
|
|
|
|
|
Loss
from discontinued operations
|
|
$
|
(88,767
|
)
|
$
|
(170,212
|
)
|
The
following sets forth the assets that are held for sale that are related to
the
discontinued operations:
|
|
2007
|
|
2006
|
|
Property
and equipment, net
|
|
$
|
3,178,765
|
|
$
|
3,189,674
|
|
Goodwill
|
|
|
—
|
|
|
—
|
|
Other
assets
|
|
|
—
|
|
|
—
|
|
Total
assets of discontinued operations
|
|
$
|
3,178,765
|
|
$
|
3,189,674
|
|
5.
OTHER CURRENT ASSETS
At
March
31, 2007 and December 31, 2006, the Company had other current assets of $17,000
and $13,000, respectively, consisting primarily of security deposits.
6.
GOODWILL AND PATENTS
The
Company’s goodwill relates to its SurgiCount subsidiary. Identifiable intangible
assets, net, as of March 31, 2007 and December 31, 2006 are composed of
patents:
|
|
March
31, 2007
|
|
December
31, 2006
|
|
Patents
|
|
$
|
4,684,576
|
|
$
|
4,684,576
|
|
Accumulated
amortization
|
|
|
(676,961
|
)
|
|
(595,726
|
)
|
|
|
$
|
4,007,615
|
|
$
|
4,088,850
|
|
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
7.
LONG-TERM INVESTMENTS
Long-term
investments at March 31, 2007 and December 31, 2006 are comprised of the
following:
Alacra
Corporation
|
|
$
|
1,000,000
|
|
Digicorp
|
|
|
10,970
|
|
Investments
in Real Estate
|
|
|
430,563
|
|
|
|
$
|
1,441,533
|
|
Alacra
Corporation
At
March
31, 2007, the Company had an investment in shares of Series F convertible
preferred stock of Alacra Corporation (“Alacra”),
valued
at $1,000,000, and classified as an available-for-sale investment. The Company
has the right, to the extent that Alacra has sufficient available capital,
to
have the Series F convertible preferred stock redeemed by Alacra for face value
plus accrued dividends beginning on December 31, 2006. Alacra, based in New
York, is a global provider of business and financial information.
Digicorp
At
March
31, 2007, the Company held 96,269 shares of Digicorp common stock valued at
$10,970. Digicorp's common stock is quoted on the OTC Bulletin Board. During
the
three months ended March 31, 2007 the closing prices for Digicorp’s common stock
ranged between $0.08 and $0.18 per share. At March 31, 2007, the quoted closing
price was $0.13 per share.
Investments
in Real Estate
At
March
31, 2007, the Company had several real estate investments, recorded at their
cost of $430,563. These investments are included in long-term investments.
The
Company holds its real estate investments in AGB Properties. AGB Properties
real
estate holdings consist of approximately 8.5 acres of undeveloped land in Heber
Springs, Arkansas and 0.61 acres of undeveloped land in Springfield, Tennessee.
8.
NOTES PAYABLE
Notes
payable at March 31, 2007 and December 31, 2006 are comprised of the
following:
|
|
March
31, 2007
|
|
December
31, 2006
|
|
Note
payable to Winstar (a)
|
|
$
|
—
|
|
$
|
450,000
|
|
Notes
payable to Ault Glazer Capital Partners, LLC (b)
|
|
|
2,575,528
|
|
|
2,575,528
|
|
Note
payable to Steven J. Caspi (c)
|
|
|
1,000,000
|
|
|
1,000,000
|
|
Note
payable to Steven J. Caspi (d)
|
|
|
1,495,281
|
|
|
1,495,281
|
|
Notes
payable to Herb Langsam (e)
|
|
|
600,000
|
|
|
600,000
|
|
Note
payable to Charles Kalina III (f)
|
|
|
400,000
|
|
|
400,000
|
|
Other
notes payable
|
|
|
608,232
|
|
|
598,232
|
|
Total
notes payable
|
|
|
6,679,041
|
|
|
7,119,041
|
|
Less:
debt discount on beneficial conversion feature
|
|
|
(904,903
|
)
|
|
(1,074,330
|
)
|
|
|
$
|
5,774,138
|
|
$
|
6,044,711
|
|
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
Aggregate
future required principal payments on these notes during the twelve month period
subsequent to March 31, 2007 are as follows:
2007
|
|
$
|
5,184,041
|
|
2008
|
|
|
—
|
|
2009
|
|
|
—
|
|
2010
|
|
|
1,495,000
|
|
|
|
$
|
6,679,041
|
|
(a)
|
On
August 28, 2001, the Company made an investment in Excelsior Radio
Networks, Inc. (“Excelsior”)
which was completely liquidated during 2005. As part of the purchase
price
paid by the Company for its investment in Excelsior, the Company
issued a
$1,000,000 note to Winstar. This note was due February 28, 2002 with
interest at 3.54% per annum but in accordance with the agreement
has a
right of offset against certain representations and warranties made
by
Winstar. The Company applied offsets of $215,000 against the principal
balance of the note reflected in the accompanying consolidated interim
financial statements relating to legal fees attributed to our defense
of
the lawsuits filed against us. The Company has consistently asserted
that
the due date of the note is extended until the lawsuit discussed
in Note
13 is settled. However, on February 3, 2006, Winstar Global Media,
Inc.
(“WGM”)
filed a lawsuit against the Company in an attempt to collect upon
the
$1,000,000 note between the Company and Winstar. On September 5,
2006, the
Company reached a settlement agreement with WGM whereas the Company
agreed
to pay Winstar $750,000, pursuant to an agreed upon payment schedule,
on
or before July 2, 2007. On November 7, 2006, The United States Bankruptcy
Court for the District of Delaware, approved the Company’s settlement
agreement with WGM. Pursuant to the settlement agreement, the Company
made
payments of $300,000 during 2006 and the remaining $450,000 during
the
three months ended March 31, 2007. The Company recorded a gain during
2006
of $191,000 on the elimination of principal and interest in excess
of the
settlement amount.
|
(b) |
From
January 11, 2006 through June 30, 2006, Ault Glazer Capital Partners,
LLC
(formerly AGB Acquisition Fund) (the “Fund”),
a related party, loaned the Company a total of $443,000, all of which
was
repaid. As consideration for the loans, the Company issued the Fund
secured promissory notes with an interest rate of 7% per annum (the
“Fund
Notes”),
and entered into a security agreement granting the Fund a security
interest in the Company’s personal property and fixtures, inventory,
products and proceeds as security for the Company’s obligations under the
Fund Notes. During the year ended December 31, 2006, the Company
incurred
and paid interest expense of $2,000 on the Fund Notes.
|
On
February 8, 2006, the Fund loaned $687,000 to ASG and at March 31, 2007 the
entire amount was outstanding. As consideration for the loan, ASG issued the
Fund a secured promissory note in the principal amount of $687,000 (the
“ASG
Note”)
and
granted a real estate mortgage in favor of the Fund relating to certain real
property located in Jefferson County, Alabama (the “ASG
Property”).
The
ASG Note, as amended, bears interest at the rate of 10% per annum and was due
on
September 15, 2006. The ASG Note is in default and classified with current
liabilities. The Fund received warrants to purchase 20,608 shares of the
Company’s common stock at an exercise price of $3.86 per share as additional
consideration for entering into the loan agreement. The Company recorded debt
discount in the amount of $44,000 as the estimated value of the warrants. The
debt discount was amortized as non-cash interest expense over the initial term
of the debt using the effective interest method. The entire amount of the debt
discount was amortized as interest expense. As security for the performance
of
ASG’s obligations pursuant to the ASG Note, ASG granted the Fund a security
interest in all personal property and fixtures located at the ASG Property.
During the three months ended March 31, 2007 and 2006, the Company incurred
interest expense, excluding amortization of debt discount, of $17,000 and
$10,000, respectively, on the ASG Note. At March 31, 2007 accrued interest
on
the ASG Note is $78,000.
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
As
of
March 31, 2007 and December 31, 2006, the Fund loaned $1,495,000 to ASG in
addition to the ASG Note. The loans were advanced to ASG, pursuant to the terms
of a Real Estate Note dated July 27, 2005, as amended (the "Real
Estate Note").
The
Real Estate Note bears interest at the rate of 3% above the Prime Rate as
published in the Wall Street Journal (8.25% at March 31, 2007). All unpaid
principal, interest and charges under the Real Estate Note are due in full
on
July 31, 2010. The Real Estate Note is collateralized by a mortgage on certain
real estate owned by ASG pursuant to the terms of a Future Advance Mortgage
Assignment of Rents and Leases and Security Agreement dated July 27, 2005
between ASG and the Fund. During the three months ended March 31, 2007 and
2006,
the Company incurred interest expense of $41,000 and $33,000, respectively,
on
the Real Estate Note. At March 31, 2007 accrued interest on the Real Estate
Note
is $231,000.
From
March 7, 2006 through October 16, 2006, the Fund loaned the Company a total
of
$524,000, of which $130,000 was repaid. The outstanding balance at March 31,
2007 is $394,000. The loans were advanced to the Company pursuant to a Revolving
Line of Credit Agreement (the “Revolving
Line of Credit”)
entered
into with the Fund on March 7, 2006. The Revolving Line of Credit allowed the
Company to request advances of up to $500,000 from the Fund. Each advance under
the Revolving Line of Credit is evidenced by a secured promissory note and
a
security agreement. The secured promissory notes issued pursuant to the
Revolving Line of Credit required repayment with interest at the Prime Rate
plus
1% within 60 days from issuance and are convertible into shares of the Company’s
common stock at the option of the Fund at a price of $3.10 per share. The
secured promissory notes issued pursuant to the Revolving Line of Credit are
currently in default and the Company is in discussions with the Fund to
restructure these notes. The obligations of the Company pursuant to such secured
promissory notes are secured by the Company’s assets, personal property and
fixtures, inventory, products and proceeds therefrom. During the three months
ended March 31, 2007 and 2006, the Company incurred interest expense of $9,000
and $200, respectively, on the Revolving Line of Credit. At March 31, 2007
accrued interest on the Revolving Line of Credit is $25,000.
(c)
|
On
January 12, 2006, Steven J. Caspi loaned $1,000,000 to ASG. As
consideration for the loan, ASG issued Mr. Caspi a promissory note
in the
principal amount of $1,000,000 (the “Caspi
Note”)
and granted Mr. Caspi a mortgage on certain real estate owned by
ASG and a
security interest on all personal property and fixtures located on
such
real estate as security for the obligations under the Caspi Note.
In
addition, the Company entered into an agreement guaranteeing ASG’s
obligations pursuant to the Caspi Note and Mr. Caspi received warrants
to
purchase 30,000 shares of the Company’s common stock at an exercise price
of $4.50 per share. The Company recorded debt discount in the amount
of
$92,000 based on the estimated fair value of the warrants. The debt
discount was amortized as non-cash interest expense over the initial
term
of the debt using the effective interest method. The entire amount
of the
debt discount was amortized as interest expense. The Caspi Note initially
accrued interest at the rate of 10% per annum, which together with
principal, was due to be repaid on July 13, 2006. The Caspi Note
was not
repaid by the scheduled maturity and to date has not been extended,
therefore the Caspi Note is recorded in current liabilities. The
Caspi
Note is in default and therefore accruing interest at the rate of
18% per
annum. During the three months ended March 31, 2007 and 2006, the
Company
incurred interest expense of $44,000 and $21,000, respectively, on
the
Caspi Note. At March 31, 2007 accrued interest on the Caspi Note
is
$120,000.
|
(d)
|
From
September 8, 2006 through September 19, 2006, Mr. Caspi loaned the
Company
a total of $1,495,000, all of which is outstanding at March 31, 2007.
As
consideration for the loan, the Company issued Mr. Caspi a Convertible
Promissory Note in the principal amount of $1,495,000 (the “Second
Caspi Note”).
The Second Caspi Note bears interest at the rate of 12% per annum
and is
due upon the earlier of March 31, 2008 or, the occurrence of an event
of
default. As security for the performance of the Company’s obligations
pursuant to the Second Caspi Note, the Company granted Mr. Caspi
a
security interest in certain real property. Mr. Caspi received warrants
to
purchase 250,000 shares of the Company’s common stock at an exercise price
of $1.25 per share as additional consideration for entering into
the loan
agreement. During the three months ended March 31, 2007, the Company
had
incurred interest expense, excluding amortization of debt discount,
of
$44,000 on the Second Caspi Note. At March 31, 2007 accrued interest
on
the Second Caspi Note is $100,000.
|
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
As
the
effective conversion price of the Second Caspi Note on the date of issuance
was
below the fair market value of the underlying common stock, the Company recorded
debt discount in the amount of $769,000 based on the intrinsic value of the
beneficial conversion feature of the note.
The
warrant issued to Mr. Caspi in conjunction with the Second Caspi Note will
expire after September 8, 2011. The Company recorded debt discount in the amount
of $231,000 based on the estimated fair value of the warrants. The debt discount
as a result of the beneficial conversion feature of the note and the estimated
fair value of the warrants will be amortized as non-cash interest expense over
the term of the debt using the effective interest method. During the three
months ended March 31, 2007, interest expense of $123,000 has been recorded
from
the debt discount amortization.
(e) |
On
May 1, 2006, Herbert Langsam, a Class II Director of the Company,
loaned
the Company $500,000. The loan is documented by a $500,000 Secured
Promissory Note (the “Langsam
Note”)
payable to the Herbert Langsam Irrevocable Trust. The Langsam Note
accrues
interest at the rate of 12% per annum and had a maturity date of
November
1, 2006. This note was not repaid by the scheduled maturity and to
date
has not been extended, therefore the Langsam Note is recorded in
current
liabilities. Accordingly, the note is currently in default and therefore
accruing interest at the rate of 16% per annum. Pursuant to the terms
of a
Security Agreement dated May 1, 2006, the Company granted the Herbert
Langsam Revocable Trust a security interest in all of the Company’s assets
as collateral for the satisfaction and performance of the Company’s
obligations pursuant to the Langsam
Note.
|
On
November 13, 2006, Mr. Langsam, loaned the Company an additional $100,000.
The
loan is documented by a $100,000 Secured Promissory Note (the “Second
Langsam Note”)
payable
to the Herbert Langsam Irrevocable Trust. The Second Langsam Note accrues
interest at the rate of 12% per annum and has a maturity date of May 13, 2007.
Mr. Langsam received warrants to purchase 50,000 shares of the Company’s common
stock at an exercise price of $1.25 per share as additional consideration for
entering into the loan agreement. The Company recorded debt discount in the
amount of $17,000 as the estimated value of the warrants. The debt discount
will
be amortized as non-cash interest expense over the term of the debt using the
effective interest method. During the three months ended March 31, 2007,
interest expense of $7,000 has been recorded from the debt discount
amortization. Pursuant to the terms of a Security Agreement dated November
13,
2006, the Company granted the Herbert Langsam Revocable Trust a security
interest in all of the Company’s assets as collateral for the satisfaction and
performance of the Company’s obligations pursuant to the Second Langsam Note.
During
the three months ended March 31, 2007, the Company incurred interest expense,
excluding amortization of debt discount, of $8,000 on the Langsam Notes. At
March 31, 2007 accrued interest on the Langsam Notes is $58,000.
(f) |
On
July 12, 2006 the Company, executed a Convertible Promissory Note
in the
principal amount of $250,000 (the “Kalina
Note”)
and a warrant for the purchase of 85,000 Shares of the Company’s Common
Stock (the “Kalina
Warrant”)
in favor of Charles J. Kalina, III, an existing shareholder of the
Company. The Kalina Note accrued interest at the rate of 12% per
annum
throughout the term of the loan. The principal amount of the Kalina
Note
and any accrued but unpaid interest was due to be paid upon the earlier
of
October 10, 2006. Principal and interest on the Kalina Note was
convertible into shares of the Company’s common stock at a conversion
price of $3.00.
|
The
Kalina Warrant has an exercise price of $ 2.69 per share and will expire on
July
11, 2011. The Company recorded debt discount in the amount of $161,000 based
on
the estimated fair value of the Kalina Warrants. The debt discount was amortized
as non-cash interest expense over the initial term of the debt using the
effective interest method.
|
On
November 3, 2006 the balance due under the Kalina Note was added
to a new
Convertible Promissory Note in the principal amount of $400,000 (the
“Second
Kalina Note”),
pursuant to which the Company received proceeds of approximately
$150,000.
The Second Kalina Note bears interest at the rate of 12% per annum
and is
due on January 31, 2008 or, the occurrence of an event of default.
Mr.
Kalina received warrants to purchase 250,000 shares of the Company’s
common stock at an exercise price of $1.25 per share as additional
consideration for entering into the loan agreement. During the three
months ended March 31, 2007, the Company incurred interest expense,
excluding amortization of debt discount, of $12,000 on the Second
Kalina
Note. At March 31, 2007 accrued interest on the Second Kalina Note
is
$12,000.
|
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
As
the
effective conversion price of the Second Kalina Note on the date of issuance
was
below the fair market value of the underlying common stock, the Company recorded
debt discount in the amount of $77,000 based on the intrinsic value of the
beneficial conversion feature of the note.
The
warrant issued to Mr. Kalina in conjunction with the Second Kalina Note will
expire after November 3, 2011. The Company recorded debt discount in the amount
of $29,000 based on the estimated fair value of the warrants. The debt discount
as a result of the beneficial conversion feature of the note and the estimated
fair value of the warrants will be amortized as non-cash interest expense over
the term of the debt using the effective interest method. During the three
months ended March 31, 2007, interest expense of $23,000 has been recorded
from
the debt discount amortization.
9.
ACCRUED LIABILITIES
Accrued
liabilities at March 31, 2007 and December 31, 2006 are comprised of the
following:
|
|
March
31, 2007
|
|
December
31, 2006
|
|
Accrued
interest
|
|
$
|
685,001
|
|
$
|
520,114
|
|
Accrued
professional fees
|
|
|
10,000
|
|
|
10,000
|
|
Accrued
dividends
|
|
|
114,975
|
|
|
95,812
|
|
Accrued
salaries
|
|
|
53,659
|
|
|
197,495
|
|
Other
|
|
|
65,339
|
|
|
1,045
|
|
|
|
$
|
928,974
|
|
$
|
824,466
|
|
10.
EQUITY TRANSACTIONS
On
January 29, 2007, the Company entered into a subscription agreement with A
Plus,
pursuant to which the Company sold to A Plus 800,000 shares of its common stock
and warrants to purchase an additional 300,000 shares of its common stock.
The
Company received gross proceeds of $500,000 in cash and will receive $500,000
in
product over the course of the next twelve (12) months. The Warrant shall have
a
term of five (5) years and shall have an exercise price equal to $2.00 per
share.
Between
January 29, 2007 and April 5, 2007, the Company entered into a subscription
agreement with several accredited investors in a private placement exempt from
the registration requirements of the Securities Act of 1933, as amended (the
“Securities
Act”).
The
Company issued and sold to these accredited investors an aggregate of 2,104,000
shares of its common stock and warrants to purchase an additional 1,052,000
shares of its common stock. The warrants are exercisable for a period of three
to five years, have an exercise price equal to $2.00, and 50% of the warrants
are callable upon the occurrence of any one of a number of specified events
when, after any such specified occurrence, the average closing price of the
Company’s common stock during any period of five consecutive trading days
exceeds $4.00 per share. These issuances resulted in aggregate gross proceeds
to
the Company of $2,630,000.
11.
WARRANTS
During
the three months ended March 31, 2007, a total of 1,315,120 warrants, at an
exercise price of $2.00 per share were issued. The warrants were valued using
the Black-Scholes valuation model assuming expected dividend yield, risk-free
interest rate, expected life and volatility of 0%, 4.50%, five years and 63%,
respectively. Warrants granted during the year ended December 31, 2006 were
valued using an expected dividend yield, risk-free interest rate, expected
life
and volatility of 0%, 3.75% - 4.50%, three to five years and 63% - 88%,
respectively. As of March 31, 2007, a total of 4,589,641 warrants, at exercise
prices ranging from $1.25 to $6.05 remain outstanding.
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
12.
RELATED PARTY TRANSACTIONS
During
the three months ended March 31, 2007 and year ended December 31, 2006, the
Company paid approximately 25% of the base rent on the corporate offices and
The
Ault Glazer Group, Inc. ("Ault
Glazer"),
based
upon their usage of the facilities, paid the remaining base rent. Together,
Milton “Todd” Ault III, our former Chairman and Chief Executive Officer of the
Company, and Louis Glazer, a Class I Director of the Company, and Melanie
Glazer, the former Manager of our real estate segment, (together, the
“Glazers”)
own a
controlling interest in the outstanding capital stock of Ault Glazer. As of
March 31, 2007 and December 31, 2006, Ault Glazer, Mr. Ault and the Glazers
indirectly beneficially own or control approximately 26% and 40%, respectively,
of the outstanding common stock of the Company and beneficially own
approximately 98.2% of the outstanding preferred stock of the Company.
IPEX,
Inc.
On
June
30, 2005, the Company formalized the terms of a consulting agreement, consented
to by IPEX, whereby the Company was retained by the majority shareholder of
IPEX
and former President, Chief Executive Officer and director of IPEX (“Majority
Shareholder”),
to
serve as a business consultant to IPEX. At June 30, 2005, Mr. Ault, the
Company’s Chairman and Chief Executive Officer at that time, was granted an
irrevocable voting proxy for 18,855,900 shares of IPEX owned by the Majority
Shareholder (representing approximately 67% of the then outstanding shares
of
IPEX). At December 31, 2005, the Company held 7.8% of IPEX’s outstanding shares
of common stock. On June 30, 2005, the Company agreed with IPEX as to the scope
of such consulting services and the consideration for such services. The Company
initially valued the amount of the consulting services at $1,331,000, which
was
due on August 15, 2005. The Company received 500,000 shares of IPEX common
stock
in December 2005 as payment for the services. At the time of payment, the fair
market value of IPEX common stock had decreased by approximately 33%.
Accordingly, the Company reduced the initial value of the consulting services
by
the amount of the decrease in the fair market value of IPEX common stock,
$675,000. As a result of the decrease in the fair market value of IPEX common
stock, the Company ultimately recognized $656,000 in revenue as a result of
this
agreement, of which $55,000 was recognized during the three months ended March
31, 2006.
The
Company’s former Chairman and Chief Executive Officer and significant beneficial
owner of the Company, Milton “Todd” Ault III, served as a director of IPEX.
Further, the Chief Executive Officer of ASG served as an IPEX director and
member of IPEX’s Audit Committee from August 2005 through January
2006.
Digicorp
At
March
31, 2007 and December 31, 2006, the Company had an investment in Digicorp
recorded in long-term investments. The Company’s Chief Executive Officer and
Chief Financial Officer, William B. Horne, was also Chief Financial Officer
of
Digicorp and remains a director of the Company. Further, certain Company
officers and directors, both past and present, served in various management
and
director roles at Digicorp.
Loans
During
the three months ended March 31, 2007 and the year ended December 31, 2006,
the
Company received loans from Ault Gazer Capital Partners, LLC (the “Fund”).
Ault
Glazer & Company Investment Management, LLC (“AG
& Company IM”)
is the
managing member of the Fund. The managing member of AG & Company IM is Ault
Glazer. Mr. Ault is Chairman, Chief Executive Officer and President of Ault
Glazer. Until June 8, 2006, the Company’s current Chief Executive Officer, Chief
Financial Officer and Director, William B. Horne, was also Chief Financial
Officer of Ault Glazer.
Patient
Safety Technologies, Inc. and Subsidiaries
Notes
to Consolidated Interim Financial Statements - Unaudited
(continued)
13.
COMMITMENTS AND CONTINGENCIES
Legal
Proceedings
On
October 15, 2001, Jeffrey A. Leve and Jeffrey Leve Family Partnership, L.P.
filed a lawsuit (the “Leve
Lawsuit”)
against
the Company, Sunshine Wireless, LLC ("Sunshine"),
and
four other defendants affiliated with Winstar Communications, Inc. (“Winstar”).
On
February 25, 2003, the case against the Company and Sunshine was dismissed,
however, on October 19, 2004, Jeffrey A. Leve and Jeffrey Leve Family
Partnership, L.P. exercised their right to appeal. The initial lawsuit alleged
that the Winstar defendants conspired to commit fraud and breached their
fiduciary duty to the plaintiffs in connection with the acquisition of the
plaintiff's radio production and distribution business. The complaint further
alleged that the Company and Sunshine joined the alleged conspiracy. On June
1,
2005, the United States Court of Appeals for the Second Circuit affirmed the
February 25, 2003 judgment of the district court dismissing the claims against
the Company.
On
July
28, 2005, Jeffrey A. Leve and Jeffrey Leve Family Partnership, L.P. filed a
new
lawsuit (the “new
Leve Lawsuit”)
against
the Company, Sunshine Wireless, LLC ("Sunshine"),
and
four other defendants affiliated with Winstar Communications, Inc. (“Winstar”).
The
new Leve Lawsuit attempts to collect a federal default judgment of $5,014,000
entered against only two entities, i.e., Winstar Radio Networks, LLC and Winstar
Global Media, Inc., by attempting to enforce the judgment against a number
of
additional entities who are not judgment debtors. Further, the new Leve Lawsuit
attempts to enforce the plaintiffs default judgment against entities who were
dismissed on the merits from the underlying action in which plaintiffs obtained
their default judgment. An unfavorable outcome in the lawsuit, may have a
material adverse effect on the Company's business, financial condition and
results of operations. The Company believes the lawsuit is without merit and
intends to vigorously defend itself. These consolidated interim financial
statements do not include any adjustments for the possible outcome of this
uncertainty.
14.
SEGMENT REPORTING
The
Company reports segment information in accordance with SFAS No. 131,
Disclosures
about Segments of an Enterprise and Related Information.
The
segment information previously provided reflected the three distinct lines
of
business within the Company’s past organizational structure: medical
products, financial services and real estate, and
car
wash services.
The
Company has restructured its operations such that its only continuing operations
are related to the medical products segment. Accordingly, since the Company
only
operates within a single industry, segment information is no longer
reported.
15.
SUBSEQUENT EVENTS
On
April
4, 2007, ASG entered into an agreement for the sale of real property located
in
Tuscaloosa, Alabama (the “Tuscaloosa Undeveloped Land”) to Twin Properties, LLC.
Pursuant to the agreement, ASG is responsible for obtaining title insurance,
all
required taxes related to the transaction and providing a marketable title
in
fee simple to Twin Properties, LLC. ASG agreed to sell the Tuscaloosa
Undeveloped Land for a purchase price of $965,000. This transaction is expected
to close in July 2007.
On
April
26, 2007, ASG entered into a binding term sheet to sell its express car wash
and
a parcel of real property, both located in Birmingham, Alabama, to Charles
H.
Dellaccio and D.W. Grimsley, Jr. Mr. Grimsley is the Chairman of the Board
and
Chief Executive Officer of Automotive Services Group. The aggregate purchase
price for both properties is $2.25 million.
This
transaction is expected to close in July 2007.
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of
Operations.
The
following discussion and analysis of our financial condition and results of
operations should be read in conjunction with our financial statements and
the
related notes thereto contained elsewhere in this Form 10-Q. This
discussion contains forward-looking statements that involve risks and
uncertainties. All statements regarding future events, our future financial
performance and operating results, our business strategy and our financing
plans
are forward-looking statements. In many cases, you can identify forward-looking
statements by terminology, such as “may,” “should,” “expects,” “intends,”
“plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or
“continue” or the negative of such terms and other comparable terminology. These
statements are only predictions. Known and unknown risks, uncertainties and
other factors could cause our actual results to differ materially from those
projected in any forward-looking statements. In evaluating these statements,
you
should specifically consider various factors, including, but not limited to,
those set forth in Part II of this report under “Item 1A. Risk Factors” and
elsewhere in this report on Form 10-Q.
The
following “Overview” section is a brief summary of the significant issues
addressed in Management’s Discussion and Analysis of Financial Condition and
Results of Operations (“MD&A”).
Investors should read the relevant sections of the MD&A for a complete
discussion of the issues summarized below. The entire MD&A should be read in
conjunction with Item 1 of Part I of this report, “Financial
Statements.”
Overview
Until
March 31, 2005, Patient Safety Technologies, Inc., a Delaware corporation
(referred to herein as the “Company,”
“we,” “us,”
and
“our”
),
elected to be a Business Development Company ( “BDC”
) under
the Investment Company Act of 1940, as amended (the “1940
Act”
). On
March 30, 2005, stockholder approval was obtained to withdraw our election
to be
treated as a BDC and on March 31, 2005 we filed an election to withdraw our
election with the Securities and Exchange Commission. At March 31, 2007, 7.75%
of our assets, consisting primarily of our investment in Alacra Corporation,
on
a consolidated basis with subsidiaries were comprised of investment securities
within the meaning of the 1940 Act (“Investment
Securities”).
We
continue to evaluate ways in which we can dispose of these Investment Securities
so that we can direct our efforts to our fundamental business strategy of equity
growth through creating, building and operating companies
in the patient safety medical products industry.
We
have
two wholly-owned operating subsidiaries: (1) SurgiCount Medical, Inc., a
California corporation; and (2) Automotive Services Group, Inc., (formerly
known
as Ault Glazer Bodnar Merchant Capital, Inc.) a Delaware
corporation.
We
are
engaged in the acquisition of controlling interests in companies and research
and development of products and services focused primarily in the health care
and medical products field, particularly the patient safety markets. SurgiCount
is a developer and manufacturer of patient safety products and services. In
the
past we also focused on the financial services and real estate industries,
however, on March 29, 2006, our Board of Directors determined to focus our
business on the patient safety medical products field. Automotive Services
Group
holds our investment in ASG, its wholly-owned express car wash subsidiary.
In
addition to the assets that are held in Automotive Services Group, we hold
various other unrelated investments which we are in the process of liquidating.
The unrelated investments are included in a separate segment, financial services
and real estate. We purchased the remaining equity interest in ASG in March
2006
and during the fourth quarter of 2006 we began marketing for sale the assets
held in ASG.
SurgiCount’s
Safety-Sponge™ System helps reduce the number of retained sponges and towels in
patients during surgical procedures and allows for faster and more accurate
counting of surgical sponges. The SurgiCount Safety-SpongeTM
System
is
a patented turn-key array of modified surgical sponges, line-of-sight scanning
SurgiCounters, and printPAD printers integrated together to form a comprehensive
counting and documentation system. The Safety-Sponge System works much like
a
grocery store checkout process: Every surgical sponge and towel is affixed
with
a unique inseparable two-dimensional data matrix bar code and used with a
SurgiCounter to scan and record the sponges during the initial and final counts.
Because each sponge is identified with a unique code, a SurgiCounter will not
allow the same sponge to be counted more than one time. When counts have been
completed at the end of a procedure, the system will produce a printed report,
or can be modified to work with a hospital's paperless system. By scanning
the
surgical dressings in at the beginning of a surgical procedure and then scanning
them out at the end of the procedure, the sponges can be counted faster and
more
accurately than traditional methods which require two medical personnel manually
counting the used and un-used sponges. The Safety-Sponge System is the only
FDA
510k approved computer assisted sponge counting system. SurgiCount
is the first acquisition in our plan to become a leader in the patient safety
market.
Our
principal executive offices are located at 27555 Ynez Road, Suite 330, Temecula,
CA 92591. Our telephone number is (951) 587-6201. Our website is located at
http://www.patientsafetytechnologies.com
.
Critical
accounting policies and estimates
The
below
discussion and analysis of our financial condition and results of operations
is
based upon the accompanying financial statements. The preparation of financial
statements in conformity with accounting principles generally accepted in the
United States of America requires management to make estimates and assumptions
that affect the amounts reported in the financial statements. Critical
accounting policies are those that are both important to the presentation of
our
financial condition and results of operations and require management's most
difficult, complex, or subjective judgments, often as a result of the need
to
make estimates of matters that are inherently uncertain. Our most critical
accounting policy relates to the valuation of our investments in non-marketable
equity securities, valuation of our intangible assets and stock based
compensation.
Valuation
of Non-Marketable Equity Securities
In
the
past we invested in illiquid equity securities acquired directly from issuers
in
private transactions. These investments are generally subject to restrictions
on
resale or otherwise are illiquid and generally have no established trading
market. Additionally, our investment in Alacra, our only remaining investment
in
a privately held company, will not be eligible for sale to the public without
registration under the Securities Act of 1933. Because of the type of
investments that we made and the nature of our business, our valuation process
requires an analysis of various factors.
Investments
in non-marketable securities are inherently risky and the one remaining
privately held company that we have invested in may fail. Its success (or lack
thereof) is dependent upon product development, market acceptance, operational
efficiency and other key business success factors. In addition, depending on
its
future prospects, it may not be able to raise additional funds when needed
or it
may receive lower valuations, with less favorable investment terms than in
previous financings, likely causing our investments to become
impaired.
We
review
all of our investments quarterly for indicators of impairment; however, for
non-marketable equity securities, the impairment analysis requires significant
judgment to identify events or circumstances that would likely have a material
adverse effect on the fair value of the investment. The indicators that we
use
to identify those events or circumstances includes as relevant, the nature
and
value of any collateral, the portfolio company’s ability to make payments and
its earnings, the markets in which the portfolio company does business,
comparison to valuations of publicly traded companies, comparisons to recent
sales of comparable companies, the discounted value of the cash flows of the
portfolio company and other relevant factors. Because such valuations are
inherently uncertain and may be based on estimates, our determinations of fair
value may differ materially from the values that would be assessed if a liquid
market for these securities existed.
Investments
identified as having an indicator of impairment are subject to further analysis
to determine if the investment is other than temporarily impaired, in which
case
we write the investment down to its impaired value. When a portfolio company
is
not considered viable from a financial or technological point of view, we write
down the entire investment since we consider the estimated fair market value
to
be nominal. If a portfolio company obtains additional funding at a valuation
lower than our carrying amount or requires a new round of equity funding to
stay
in operation and the new funding does not appear imminent, we presume that
the
investment is other than temporarily impaired, unless specific facts and
circumstances indicate otherwise.
Security
investments which are publicly traded on a national securities exchange or
over-the-counter market are stated at the last reported sale price on the day
of
valuation or, if no sale was reported on that date, then the securities are
stated at the last quoted bid price. We may determine, if appropriate, to
discount the value where there is an impediment to the marketability of the
securities held.
Valuation
of Intangible Assets
We
assess
the impairment of intangible assets when events or changes in circumstances
indicate that the carrying value of the assets or the asset grouping may not
be
recoverable. Factors that we consider in deciding when to perform an impairment
review include significant under-performance of a product line in relation
to
expectations, significant negative industry or economic trends, and significant
changes or planned changes in our use of the assets. Recoverability of
intangible assets that will continue to be used in our operations is measured
by
comparing the carrying amount of the asset grouping to our estimate of the
related total future net cash flows. If an asset grouping’s carrying value is
not recoverable through the related cash flows, the asset grouping is considered
to be impaired. The impairment is measured by the difference between the asset
grouping’s carrying amount and its fair value, based on the best information
available, including market prices or discounted cash flow analysis. Impairments
of intangible assets are determined for groups of assets related to the lowest
level of identifiable independent cash flows. Due to our limited operating
history and the early stage of development of some of our intangible assets,
we
must make subjective judgments in determining the independent cash flows that
can be related to specific asset groupings. To date we have not recognized
impairments on any of our intangible assets related to the Safety Sponge™
System.
Stock-Based
Compensation
We
have
adopted the provisions of SFAS No. 123(R), Share-Based
Payment,
effective January 1, 2005 using
the
modified retrospective application method as provided by SFAS 123(R) and
accordingly, financial statement amounts for the prior periods in which the
Company granted employee stock options have been restated to reflect the fair
value method of expensing prescribed by SFAS 123(R). The
fair
value of each option grant, nonvested stock award and shares issued under the
employee stock purchase plan were estimated on the date of grant using the
Black-Scholes option pricing model and various inputs to the model. Expected
volatilities were based on historical volatility of our stock. The expected
term
represents the period of time that grants and awards are expected to be
outstanding. The risk-free interest rate approximates the U.S. treasury
rate corresponding to the expected term of the option, and dividends were
assumed to be zero. These inputs are based on our assumptions, which include
complex and subjective variables. Other reasonable assumptions could result
in
different fair values for our stock-based awards.
Stock-based
compensation expense, as determined using the Black-Scholes option pricing
model, is recognized on a straight line basis over the service period, net
of
estimated forfeitures. Forfeiture estimates are based
on
historical data. To the extent actual results or revised estimates differ from
the estimates used, such amounts will be recorded as a cumulative adjustment
in
the period that estimates are revised.
New
Accounting Pronouncements
In
June
2006, the FASB issued FASB Interpretation No. (FIN) 48, Accounting
for Uncertainty in Income Taxes — An Interpretation of FASB Statement
No. 109,
which
prescribes a recognition threshold and measurement attribute for the financial
statement recognition and measurement of a tax position taken or expected to
be
taken in an income tax return. FIN 48 was effective for us beginning
January 1, 2007. The adoption of FIN 48 did not have a material impact on
our financial position, results of operations or cash flows.
Financial
Condition, Liquidity and Capital Resources
Our
cash
and marketable securities were $1,411,000 at March 31, 2007, versus $4,000
at
December 31, 2006. Total current liabilities were $6,292,000 at March 31, 2007,
versus $5,637,000 at December 31, 2006. Included in current liabilities at
December 31, 2006 is a note payable to Winstar Communications, Inc.
(“Winstar”),
in the
amount of $450,000, which was repaid during the three months ended March 31,
2007.
We
had a
working capital deficit of approximately $4,185,000 at March 31, 2007 and we
continue to have recurring losses. In the past we have relied upon private
placements of equity and debt securities and we may rely on private placements
to fund our capital requirements in the future. We have received a significant
amount of funding from Ault Glazer Capital Partners, LLC (formerly AGB
Acquisition Fund) (the “Fund”).
AG
Management is the managing member of the Fund. The managing member of AG
Management is The Ault Glazer Group, Inc. (“The
AG Group”)
(f/k/a
Ault Glazer Bodnar & Company, Inc.). The Company’s former Chairman and
former Chief Executive Officer, Milton “Todd” Ault, III, is Chairman, Chief
Executive Officer and President of The AG Group. At March 31, 2007 the
outstanding principal balance of loans that we have entered into with the Fund
was $2,576,000. We have begun discussions with the Fund to restructure the
terms
of these loans. At March 31, 2007 we also had outstanding promissory notes
to
primarily three additional lenders in the principal amount of
$4,104,000.
On
January 12, 2006, Steven J. Caspi (“Caspi”)
loaned
$1,000,000 to ASG. As consideration for the loan, ASG issued Caspi a promissory
note in the principal amount of $1,000,000 (the “Caspi
Note”)
and
granted Caspi a mortgage on certain real estate owned by ASG and a security
interest on all personal property and fixtures located on such real estate
as
security for the obligations under the Caspi Note. In addition, we entered
into
an agreement guaranteeing ASG’s obligations pursuant to the Caspi Note. The
Caspi Note initially accrued interest at the rate of 10% per annum, which
together with principal, was due to be repaid on July 13, 2006. The Caspi Note
was not repaid by the scheduled maturity and to date has not been extended.
The
Caspi Note is in default and therefore accruing interest at the rate of 18%
per
annum.
From
September 8, 2006 through September 19, 2006, Caspi loaned the Company a total
of $1,495,000, all of which is outstanding at March 31, 2007. As consideration
for the loan, the Company issued Caspi a Convertible Promissory Note in the
principal amount of $1,495,000 (the “Second
Caspi Note”).
The
Second Caspi Note bears interest at the rate of 12% per annum and is due upon
the earlier of March 31, 2008 or, the occurrence of an event of default, and
is
convertible into shares of the Company’s common stock at $1.25 per share. As
security for the performance of the Company’s obligations pursuant to the Second
Caspi Note, the Company granted Caspi a security interest in certain real
property.
On
May 1,
2006, Herbert Langsam, a Class II Director of the Company, loaned the Company
$500,000. The loan is documented by a $500,000 Secured Promissory Note (the
“Langsam
Note”).
The
Langsam Note accrues interest at the rate of 12% per annum and had a maturity
date of November 1, 2006. The Langsam Note is in default and classified with
current liabilities on the balance sheet. As a result of the default, the
interest rate increased to 16% per annum.
On
November 13, 2006, Mr. Langsam loaned the Company an additional $100,000. The
loan is documented by a $100,000 Secured Promissory Note (the “Second
Langsam Note”).
The
Second Langsam Note accrues interest at the rate of 12% per annum and had a
maturity date of May 13, 2007. The Second Langsam Note is in default and
classified with current liabilities on the balance sheet. As a result of the
default the interest rate increased to 16% per annum.
Pursuant
to the terms of Security Agreements dated May 1, 2006 and November 13, 2006,
the
Company granted the Herbert Langsam Revocable Trust a security interest in
all
of the Company’s assets as collateral for the satisfaction and performance of
the Company’s obligations under the terms of the Langsam Note and the Second
Langsam Note.
On
November 3, 2006, we entered into a convertible promissory note in the principal
amount of $400,000 with Charles J. Kalina, III (the “Kalina
Note”).
The
Kalina Note bears interest at the rate of 12% per annum, is due to be paid
on
January 31, 2008, and is convertible into shares of the Company’s common stock
at $1.25 per share.
In
August
2006, we entered into subscription agreements with two unaffiliated accredited
investors, pursuant to which we sold 200,000 shares of the Company’s common
stock, $0.33 par value per share, at a price of $1.25 per share. We received
gross proceeds of approximately $250,000 from the sale of our common stock
to
the accredited investors. Pursuant to the subscription agreement, we granted
the
accredited investors piggy back registration rights to register the resale
of
the shares of common stock.
Between
November 30, 2006 and December 15, 2006, the Company entered into a subscription
agreement and sold an aggregate of 238,000 shares of its Common Stock and
warrants to purchase an aggregate of up to 119,000 shares of its Common Stock
in
a private placement transaction to certain unaffiliated accredited investors.
The warrants are exercisable for a period of three years, have an exercise
price
equal to $2.00, and 50% of the warrants are callable upon the occurrence of
any
one of a number of specified events when, after any such specified occurrence,
the average closing price of the Company’s common stock during any period of
five consecutive trading days exceeds $4.00 per share. Pursuant to the
subscription agreement, we granted the accredited investors piggy back
registration rights to register the resale of the shares of common stock. We
received aggregate gross proceeds of $298,000.
On
January 29, 2007, the Company entered into a subscription agreement and sold
an
aggregate of 800,000 shares of its Common Stock and warrants to purchase an
aggregate of up to 300,000 shares of its Common Stock in a private placement
transaction to A Plus, an accredited investor. The warrants are exercisable
for
a period of five years, have an exercise price equal to $2.00, and 50% of the
warrants are callable upon the occurrence of any one of a number of specified
events when, after any such specified occurrence, the average closing price
of
the Company’s common stock during any period of five consecutive trading days
exceeds $4.00 per share. The Company received gross proceeds of $500,000 in
cash
and will receive $500,000 in product over the course of the next twelve (12)
months. We used the net proceeds from the private placement transaction
primarily for general corporate purposes and repayment of existing liabilities.
Pursuant to the subscription agreement, we granted the accredited investors
piggy back registration rights to register the resale of the shares of common
stock.
On
January 29, 2007, the Company entered into a subscription agreement with several
unaffiliated accredited investors in a private placement exempt from the
registration requirements of the Securities Act. The Company issued and sold
to
these accredited investors an aggregate of 104,000 shares of its common stock
and warrants to purchase an additional 52,000 shares of its common stock. The
warrants are exercisable for a period of five years, have an exercise price
equal to $2.00, and 50% of the warrants are callable upon the occurrence of
any
one of a number of specified events when, after any such specified occurrence,
the average closing price of the Company’s common stock during any period of
five consecutive trading days exceeds $4.00 per share. These issuances resulted
in aggregate gross proceeds to the Company of $130,000. We used the net proceeds
from the private placement transaction primarily for general corporate purposes
. Pursuant to the subscription agreement, we granted the accredited investors
piggy back registration rights to register the resale of the shares of common
stock.
Between
March 7, 2007 and April 5, 2007, the Company entered into a subscription
agreement with several accredited investors in a private placement exempt from
the registration requirements of the Securities Act. The Company issued and
sold
to these accredited investors an aggregate of 2,000,000 shares of its common
stock and warrants to purchase an additional 1,000,000 shares of its common
stock. The warrants are exercisable for a period of five years, have an exercise
price equal to $2.00, and 50% of the warrants are callable upon the occurrence
of any one of a number of specified events when, after any such specified
occurrence, the average closing price of the Company’s common stock during any
period of five consecutive trading days exceeds $4.00 per share. These issuances
resulted in aggregate gross proceeds to the Company of $2,500,000. We are
required to use our reasonable best efforts to cause the registration statement
to become effective within 120 days after the Closing Date, April 5, 2007.
If
the registration statement has not been filed on or prior to the 120th day
after
the Closing Date, we will issue, as liquidated damages, to the purchasers of
the
2,000,000 shares of our Common Stock and the warrants to purchase 1,000,000
shares of our Common Stock warrants with a term of five years and an exercise
price of $2.00 per share to purchase shares of our Common Stock equal to 2.5%
of
the number of shares of Common Stock purchased by the purchasers. We intend
to
use the net proceeds from this private placement transaction primarily for
general corporate purposes and repayment of existing liabilities.
On
April
4, 2007, ASG entered into an agreement for the sale of real property located
in
Tuscaloosa, Alabama for $965,000 and on April 26, 2007, ASG entered into a
binding term sheet to sell its express car wash and a parcel of real property,
both located in Birmingham, Alabama, to Charles H. Dellaccio and Darrell
Grimsley for $2.25 milllion. Mr. Grimsley is the Chairman of the Board and
Chief
Executive Officer of Automotive Services Group. There can be no guarantee that
the execution of these contracts will result
in
the consummation of the transactions. However, to the extent we are successful
in consummating these transactions then we would expect to receive proceeds
from
the transactions in July 2007. If
all
the properties are sold, we will receive gross proceeds of approximately $3.2
Million. By selling these assets we will be better positioned to aggressively
pursue the market for surgical sponges in the United States and Europe, which
we
believe represents a market opportunity equal to or in excess of $650 million
in
annual sales.
Management
is currently seeking additional financing and believes that it will be
successful. However, in the event management is not successful in obtaining
additional financing, existing cash resources, together with proceeds from
investments and anticipated revenues from operations, may not be adequate to
fund our operations for the twelve months subsequent to March 31, 2007. However,
ultimately long-term liquidity is dependent on our ability to attain future
profitable operations. We intend to undertake additional debt or equity
financings to better enable us to grow and meet future operating and capital
requirements.
As
of
March 31, 2007, other than our office lease and employment agreements with
key
executive officers, we had no commitments not reflected in our consolidated
financial statements.
Cash
increased by $1,407,000 to $1,411,000 during the three months ended March 31,
2007, compared to a decrease of $22,000 during the three months ended March
31,
2006.
Operating
activities used $971,000 of cash during the three months ended March 31, 2007,
compared to providing $7,000 during the three months ended March 31,
2006.
Operating
activities for the three months ended March 31, 2007, exclusive of changes
in
operating assets and liabilities, used $860,000 of cash, as the Company's net
cash used in operating activities of $971,000 included non-cash charges for
depreciation and amortization of $113,000, debt discount of $169,000 and stock
based compensation of $312,000. For the three months ended March 31, 2006,
operating activities, exclusive of changes in operating assets and liabilities,
used $1,024,000 of cash, as the Company's net cash used in operating activities
of $7,000 included non-cash charges for depreciation and amortization of
$90,000, debt discount of $75,000, realized losses of $136,000, unrealized
gains
of $77,000 and stock based compensation of $2,354,000
Changes
in operating assets and liabilities used cash of $111,000 during the three
months ended March 31, 2007, principally due to decreases in the level of
accounts payable and accrued liabilities which were partially offset by a
decrease in prepaid expenses. During the three months ended March 31, 2006,
changes in operating assets and liabilities provided cash of $1,031,000,
principally due to net proceeds received from marketable securities, and
decreases in our receivables from investments which were partially offset by
decreases in the level of accounts payable and accrued liabilities and amounts
due to our broker. The amount due to our broker was directly attributable to
purchases of marketable investment securities that were purchased on margin
or
to securities that were margined subsequent to their purchase. During the three
months ended March 31, 2006 we invested our cash balances in the public equity
and debt markets in an attempt to maximize the short-term return on such assets.
The amount due to our broker varied throughout the year depending upon the
aggregate amount of marketable investment securities held by us and the level
of
borrowing against our available-for-sale securities. The actual amount of
marketable investment securities held was influenced by several factors,
including but not limited to, our expectations of potential returns available
from what we considered to be mispriced securities as well as the cash needs
of
our operating activities. During times when we were heavily invested in
marketable investment securities our liquidity position was significantly
reduced. We no longer make a practice of investing in marketable investment
securities.
The
principal factor in the $79,000 of cash used in investing activities during
the
three months ended March 31, 2007 was the capitalized costs of $73,000 related
to the ongoing development of software related to our Safety-SpongeTM
System.
The principal factor in the $2,082,000 of cash used in investing activities
during the three months ended March 31, 2006 was the purchase of land of
$1,697,000 and capitalized construction costs of $317,000 related to the
construction of our first automated car wash site by our subsidiary,
ASG.
Cash
provided by financing activities during the three months ended March 31, 2007,
of $2,457,000 resulted primarily from net proceeds from the issuance of common
stock and warrants of $2,897,000 offset by the repayment of the Winstar Note
in
the amount of $450,000. Cash provided by financing activities for the three
months ended March 31, 2006, of $2,054,000 resulted from the net proceeds from
notes payable.
Investments
Our
financial condition is partially dependent on the success of our existing
investments. On March 29, 2006 our Board of Directors directed us to liquidate
all of our investments and other assets that do not relate to the patient safety
medical products business. Some of our investments are subject to restrictions
on resale under federal securities laws and otherwise are illiquid, which will
make it difficult to dispose of the securities quickly. Since we will be forced
liquidate some or all of the investments on an accelerated timeline, the
proceeds of such liquidation may be significantly less than the value at which
we acquired the investments. The following is a discussion of our most
significant investments at March 31, 2007.
A
summary
of our investment portfolio, which is valued at $1,442,000 and represents 11.06%
of our total assets, is reflected below. Excluding our real estate investments,
our investment portfolio represents 7.75% of our total assets. The investment
portfolio is classified as long-term investments.
|
|
2007
|
|
Alacra
Corporation
|
|
$
|
1,000,000
|
|
Digicorp
|
|
|
10,969
|
|
Real
Estate
|
|
|
430,564
|
|
|
|
$
|
1,441,533
|
|
At
March
31, 2007, we had an investment in Alacra Corporation ( “Alacra”
),
valued at $1,000,000, which represents 7.67% of our total assets. On April
20,
2000, we purchased $1,000,000 worth of Alacra Series F Convertible Preferred
Stock. Alacra has recorded revenue growth in every year since the Company’s
original investment, further, Alacra is forecasting that 2007 revenues will
be
approximately $19.2 million, which would represent an increase of 22% over
2006
unaudited revenues. At December 31, 2006, Alacra reported in their unaudited
financial statements total assets of approximately $4.7 million with total
liabilities of approximately $7.4 million. Deferred revenue, which represents
subscription revenues are amortized over the term of the contract, which is
generally one year, and represented approximately $3.7 million of the total
liabilities. We have the right, subject to Alacra having the available cash,
to
have the preferred stock redeemed by Alacra over a period of three years for
face value plus accrued dividends beginning on December 31, 2006. Pursuant
to
this right, in December 2006 we informed management of Alacra that we were
exercising our right to put back one-third of our preferred stock. If Alacra
has
a sufficient amount of cash to redeem our preferred stock we would expect the
redemption to occur in the fourth quarter of 2007. In connection with this
investment, the Company was granted observer rights on Alacra board of directors
meetings.
Alacra,
a
privately held company based in New York, is a global provider of business
and
financial information. Alacra provides a diverse portfolio of fast,
sophisticated online services that allow users to quickly find, analyze, package
and present business information. Alacra’s customers include more than 750
leading financial institutions, management consulting, law and accounting firms
and other corporations throughout the world. Currently, Alacra’s largest
customer segment is investment and commercial banking, followed closely by
management consulting, law and multi-national corporations.
Alacra’s
online service allows users to search via a set of tools designed to locate
and
extract business information from the Internet and from Alacra’s library of
content. Alacra’s team of information professionals selects, categorizes and
indexes more than 45,000 sites on the Web containing the most reliable and
comprehensive business information. Simultaneously, users can search more than
100 premium commercial databases that contain financial information, economic
data, business news, and investment and market research. Alacra provides
information in the required format, gleaned from such prestigious content
partners as Thomson Financial™, Barra, The Economist Intelligence Unit, Factiva,
Mergerstat® and many others.
The
information services industry is intensely competitive and we expect it to
remain so. Although Alacra has been in operation since 1996 they are
significantly smaller in terms of revenue than a large number of companies
offering similar services. Companies such as ChoicePoint, Inc. (NYSE: CPS),
LexisNexis Group, and Dow Jones Reuters Business Interactive, LLC report
revenues that range anywhere from $100 million to several billion dollars,
as
reported by Hoovers, Inc. As such, Alacra’s competitors can offer a far greater
range of products and services, greater financial and marketing resources,
larger customer bases, greater name recognition, greater global reach and more
established relationships with potential customers than Alacra has. These larger
and better capitalized competitors may be better able to respond to changes
in
the financial services industry, to compete for skilled professionals, to
finance investment and acquisition opportunities, to fund internal growth and
to
compete for market share generally.
Digicorp
At
March
31, 2007, the Company held 96,269 shares of Digicorp common stock valued at
$10,970. Digicorp's common stock is quoted on the OTC Bulletin Board. During
the
three months ended March 31, 2007 the closing prices for Digicorp’s common stock
ranged between $0.08 and $0.18 per share. At March 31, 2007, the quoted closing
price was $0.13 per share.
We
are
required to purchase 224,000 shares of Digicorp common stock from certain
selling shareholders of Digicorp at a price of $0.145 per share at such time
that Digicorp registers the resale of the shares with the SEC. During December
2005 we extended loans of approximately $32,500 to these selling shareholders
from our working capital. Such loans represented the amount of the remaining
obligation to purchase 224,000 shares of Digicorp common stock and are secured
by the 224,000 shares of Digicorp common stock presently held by such selling
shareholders. On July 20, 2005, William B. Horne, our Chief Executive Officer,
was appointed as a director and as Chief Financial Officer of Digicorp. On
September 30, 2005, Mr. Horne was appointed as the interim Chief Executive
Officer. On December 29, 2005, William B. Horne resigned as Chief Executive
Officer and on April 20, 2007 he resigned as the Chief Financial
Officer.
Investments
in Real Estate
At
March
31, 2007, we had several real estate investments, valued at $431,000, which
represents 3.30% of our total assets. In the past we held our real estate
investments in Ault Glazer Bodnar Capital Properties, LLC (“AGB
Properties”).
AGB
Properties, which was closed during 2006, was a Delaware limited liability
company and a wholly owned subsidiary. The real estate investments, consisting
of approximately 8.5 acres of undeveloped land in Heber Springs, Arkansas and
0.61 acres of undeveloped land in Springfield, Tennessee, are currently being
marketed for sale. During the year ended December 31, 2006, we received payment
on loans that were secured by real estate of $50,000. We expect that any future
gain or loss recognized on the liquidation of some or all of our real estate
holdings would be insignificant primarily due to the short period of time that
the properties were owned combined with the absence of any significant changes
in property values in the real estate markets where the real estate holdings
are
located.
Results
of Operations
We
account for our operations under accounting principles generally accepted in
the
United States. The principal measure of our financial performance is captioned
“Net loss attributable to common shareholders,” which is comprised of the
following:
|
·
|
"Revenues,"
which is the amount we receive from sales of our
products;
|
|
·
|
“Operating
expenses,” which are the related costs and expenses of operating our
business;
|
|
|
“Interest,
dividend income and other, net,” which is the amount we receive from
interest and dividends from our short term investments and money
market
accounts, and our proportionate share of income or losses from investments
accounted for under the equity method of
accounting;
|
|
|
“Realized
gains (losses) on investments, net,” which is the difference between the
proceeds received from dispositions of investments and their stated
cost;
and
|
|
|
“Unrealized
gains (losses) on marketable securities, net,” which is the net change in
the fair value of our marketable securities, net of any (decrease)
increase in deferred income taxes that would become payable if the
unrealized appreciation were realized through the sale or other
disposition of the investment
portfolio.
|
“Realized
gains (losses) on investments, net” and “Unrealized gains (losses) on marketable
securities, net” are directly related. When a security is sold to realize a
gain, the net unrealized gain decreases and the net realized gain increases.
When a security is sold to realize a loss, the net unrealized gain increases
and
the net realized gain decreases.
We
generally earn interest income from loans, preferred stock, corporate bonds
and
other fixed income securities. The amount of interest income varies based upon
the average balance of our fixed income portfolio and the average yield on
this
portfolio.
Revenues
We
recognized revenues of $307,000 and $55,000 during the three months ended March
31, 2007 and 2006, respectively. All of the revenues generated during the three
months ended March 31, 2007 related to sales of our Safety-SpongeTM
System.
Revenues from sales of our Safety-SpongeTM
System
consisted of sales from the safety sponge of $201,000 and sales from hardware
and supplies of $106,000. Although hardware sales are not considered a recurring
item, we expect that once an institution adopts our system they will be
committed to its use and therefore provide a recurring source of revenues for
sales of the safety sponge.
During
the quarter ended March 31, 2007, sales generated by our
Safety-SpongeTM
System
exceeded all sales generated from the Safety-SpongeTM
System
during the entire year of 2006. We attribute a significant amount of the
increase to the adoption by the University
of California San Francisco Medical Center in February 2007 to our Safety-SpongeTM
System.
All
of
the revenue earned during the three months ended March 31, 2006 was the result
of a consulting agreement, consented to by IPEX, whereby the majority
shareholder of IPEX and former President, former Chief Executive Officer and
former director of IPEX (“Majority
Shareholder”),
retained us to serve as a business consultant to IPEX. In consideration for
the
services, during December 2005, the Majority Shareholder personally transferred
us 500,000 shares of common stock of IPEX as a non-refundable consulting fee.
This consulting agreement reflected our prior focus in the financial services
and real estate industries. Since we now only focus our efforts on the patient
safety markets, we do not expect revenue from these types of consulting
agreements to be a source of recurring revenue.
On
November 14, 2006, SurgiCount entered into a Supply Agreement with Cardinal
Health 200, Inc., a Delaware corporation ("Cardinal").
Pursuant to the agreement, Cardinal shall act as the exclusive distributor
of
SurgiCount's products in the United States, with the exception that SurgiCount
may sell its products to one other hospital supply company, named in the
agreement, solely for its sale/distribution to its hospital customers. The
term
of the agreement is 36 months, unless earlier terminated as set forth therein.
Otherwise, the agreement automatically renews for successive 12 month periods.
We cannot reasonably predict or estimate the financial impact of the agreement
with Cardinal but believes it will have a material impact on our results of
operations.
Expenses
Operating
expenses were $1,409,000 and $3,395,000 for the three months ended March 31,
2007 and 2006, respectively.
The
decrease in operating expenses of $1,986,000, for the three months ended March
31, 2007 when compared to the three months ended March 31, 2006, was primarily
the result of salaries and employee benefits, which decreased by $1,887,000.
Our
Compensation Committee, currently comprised of two independent directors,
determines and recommends to our Board the cash and stock based compensation
to
be paid to our executive officers and also reviews the amount of salary and
bonus for each of our other officers and employees. The most significant
component of employee compensation is stock based compensation expense.
For
the
three months ended March 31, 2007, we recorded $58,000 related to grants of
nonqualified stock options and $192,000 related to restricted stock awards
to
our employees and non-employee directors. During the three months ended March
31, 2006, we recorded $922,000 relating to grants of nonqualified stock options
and $1,014,000 related to restricted stock awards to our employees and
non-employee directors. The issuance of stock options and restricted stock
awards to our employees and non-employee directors resulted in a decrease in
stock based compensation expense of $1,686,000 for the three months ended March
31, 2007. Therefore, excluding stock based compensation, salaries and employee
benefits decreased by $201,000.
The
remaining increase of $201,000 in salaries and employee benefits is primarily
attributed to the non-recurring severance package that we paid in January 2006
to Milton “Todd” Ault III, our former Chairman and Chief Executive Officer.
Pursuant to this severance package we paid Mr. Ault $180,000. In July 2006,
subsequent to the payment of Mr. Ault’s severance package, Mr. Ault was
re-appointed as our Chief Executive Officer at a nominal salary.
At
March
31, 2007, four of our executives were covered under employment agreements.
Our
Chief Executive Officer, William B. Horne, is covered under a two year
employment agreement with annual base compensation of $250,000; our Chief
Executive Officer of SurgiCount Medical, Inc., Bill Adams is covered under
a
three year employment agreement with annual base compensation of $300,000;
our
President of Sales and Marketing of SurgiCount Medical, Inc., Richard Bertran,
is covered under a three year employment agreement with annual base compensation
of $200,000 and; our Director of Manufacturing of SurgiCount Medical, Inc.,
James Schafer, is covered under a two year employment agreement with annual
base
compensation of $100,000. None of our other executives our currently covered
under an employment agreement, therefore, we are under no financial obligation,
other than monthly salaries, for our other executive officers. Currently,
monthly gross salaries for all of our employees are $135,000. We believe, as
with all our operating expenses, that our existing cash resources, together
with
proceeds from investments, anticipated financings and expected revenues from
our
operations, should be adequate to fund our salary obligations.
The
second largest component of our operating expenses is professional fees, which
decreased by $309,000 during the three months ended March 31, 2007 compared
to
the amount reported during the three months ended March 31, 2006. This decrease
is primarily comprised of decreases in stock based compensation to outside
consultants of $312,000. During the three months ended March 31, 2006 stock
based compensation expense of $418,000 was the most significant component of
professional fees. The majority of the $418,000 that was recorded in stock
based
compensation related to a consulting agreement that we entered into in February
2006 with Analog Ventures, LLC (“Analog
Ventures”)
whereby
Analog Ventures agreed to consult with us on matters relating primarily to
the
divestiture of our non-core assets and assist us in our efforts to focus our
business exclusively on the patient safety medical products field. As an
incentive for entering into the agreement, we agreed to issue Analog Ventures
a
warrant to purchase 175,000 shares of our common stock at an exercise price
of
$3.95, exercisable for 3 years. We recognized an expense of $405,000 related
to
these warrants.
All
of
our stock based compensation issued to employees, non-employee directors and
consultants were expensed in accordance with SFAS 123(R). We valued the
nonqualified stock options and warrants using the Black-Scholes valuation model
assuming expected dividend yield, risk-free interest rate, expected life and
volatility of 0%, 3.00% to 4.50%, three to five years and 63% to 102%,
respectively. The restricted stock awards were valued at the closing price
on
the date the restricted shares were granted.
The
increase in cost of sales of $214,000 reflects a shift in our revenue mix from
revenue generated primarily through consulting services which do not have any
costs of sales to that of sales of our Safety-SpongeTM
System.
General
and administrative expenses experienced a decrease of $20,000 during the three
months ended March 31, 2007 over the prior year. As
discussed above, in Financial Condition, Liquidity and Capital Resources, we
have a
working
capital deficit of $4,185,000 and have experienced continued losses. These
financial constraints have required us to be selective in the expenses that
we
incur and where possible delay or forego an expense. This overall condition
has
resulted in the decrease in general and administrative expense. General and
administrative expenses is comprised of a combination of a several types of
expenses, none of which are significant individually.
Interest,
dividend income and other, net
We
had
interest income of $4,000 and $1,000 for the three months ended March 31, 2007
and 2006, respectively.
The
increase in interest income for the three months ended March 31, 2007 when
compared to March 31, 2006 was primarily the result of an overall increase
in
cash during the three months ended March 31, 2007.
Realized
gains (losses) on investments, net
During
the three months ended March 31, 2007 and 2006, we realized net losses of nil
and $136,000, respectively. The absence of realized gains (losses) during the
three months ended March 31, 2007 reflect the absence of trading operations
as
we focus all of our efforts solely on the Safety-SpongeTM
System
and the patient safety market. The realized loss during the three months ended
March 31, 2006 resulted primarily from the sale of 102,100 shares of Tuxis
Corporation.
Interest
expense
We
had
interest expense of $268,000 and $35,000 for the three months ended March 31,
2007 and 2006, respectively.
The
increase in interest expense for the three months ended March 31, 2007 when
compared to March 31, 2006 is primarily attributable to the non-cash interest
charges incurred as a result of the debt discount associated with our short-term
debt financings. During the three months ended March 31, 2007 and 2006, we
recorded $169,000 and $75,000, respectively, in non-cash interest charges.
The
non-cash interest charges that were incurred during the three months ended
March
31, 2006 were attributed to our car wash segment and recorded in loss from
discontinued operations. Thus, non-cash interest charges resulted in an increase
of $169,000 and represented the primary cause of the increase in interest
expense. These charges resulted from the issuance of debt that either had
conversion prices on the date of issuance that was below the fair market value
of the underlying common stock or required the issuance of warrants to purchase
shares of our common stock, which required us to record an expense based on
the
estimated fair value of the warrant. The remaining increase in interest expense
is attributable to the overall increased level of borrowings during the three
months ended March 31, 2007 over the prior year.
Unrealized
gains (losses) on marketable securities, net
During
the three months ended March 31, 2007 and 2006, unrealized appreciation of
investments increased by nil and $77,000, respectively.
Due
to
the absence of any material amount of marketable securities during the three
months ended March 31, 2007, the Company did not recognize any unrealized
appreciation. The increase in unrealized appreciation during the three months
ended March 31, 2006, was primarily due to the sale of 102,100 shares of Tuxis
Corporation common stock, which at December 31, 2005 had unrealized depreciation
of approximately $134,000. When we exit an investment and realize a loss, we
make an accounting entry to reverse any unrealized depreciation we had
previously recorded to reflect the depreciated value of the investment. The
increase in unrealized appreciation related to the sale of our shares of Tuxis
common stock was partially offset by a decrease in the value of the 95,000
shares of IPEX common stock held as trading securities. IPEX common stock is
traded on the OTC Bulletin Board, which reported a closing price, at December
31, 2005 of $2.38 per share compared with $0.88 per share at March 31, 2006.
We
valued our holdings in IPEX at a discount to the closing prices, or $1.19 and
$0.66 per share at December 31, 2005 and March 31, 2006, respectively, due
primarily to the limited average number of shares traded on the OTC Bulletin
Board.
Loss
from discontinued car was segment
The
loss
from our discontinued car was segment decreased by $81,000 during the three
months ended March 31, 2007 from a loss of $170,000 during the three months
ended March 31, 2006. ASG’s
first site, developed in Birmingham, Alabama, had its grand opening on March
8,
2006. Thus, the three months ended March 31, 2007 reflected an entire quarter
of
operations whereas the three months ended March 31, 2006 only reflected
operations for a partial quarter. During the three months ended March 31, 2007,
as a result of the full quarter of operations, revenues and operating costs
increased by $139,000 and $42,000, respectively.
Accumulated
other comprehensive income
Unrealized
gains (losses) on our investments designated as available-for-sale are recorded
in accumulated other comprehensive income. At March 31, 2007 and December 31,
2006, our remaining investments were carried at cost and therefore we did record
any unrealized gains (losses) on these investments. At March 31, 2006, our
restricted holdings in IPEX and Digicorp were classified as available-for-sale.
At March 31, 2006, the unrealized gains (losses) on our restricted holdings
in
IPEX and Digicorp amounted to ($831,000) and $2,460,000,
respectively.
Item
3. Quantitative and Qualitative Disclosures About Market
Risk.
Our
business activities contain elements of market risk. We consider a principal
type of market risk to be valuation risk. Investments and other assets are
valued at fair value as determined in good faith by our Board of Directors.
We
have
invested a substantial portion of our assets in private development stage or
start-up companies. These private businesses tend to be thinly capitalized,
unproven, small companies that lack management depth and have not attained
profitability or have no history of operations. Because of the speculative
nature and the lack of public market for these investments, there is
significantly greater risk of loss than is the case with traditional investment
securities. Although we are optimistic about the progress of our one remaining
investment in a privately held company, we understand that some venture capital
investments will be a complete loss or will be unprofitable and that some will
appear to be likely to become successful but never realize their potential.
Because
there is no public market for the equity interest in the one remaining privately
held small company in which we have invested, the valuation of such equity
interest is subject to estimation. In making our determination, we may consider
valuation information provided by an independent third party or the portfolio
company itself. In the absence of a readily ascertainable market value, the
estimated value of our equity investment may differ significantly from the
value
that would be placed on it if a liquid market for the equity interest existed.
Any changes in valuation are recorded in our consolidated statements of
operations as either "Unrealized losses on marketable securities, net” or “Other
comprehensive income."
Item
4. Controls and Procedures.
As
of the
end of the period covered by this report, we conducted an evaluation, under
the
supervision and with the participation of our chief executive officer and chief
financial officer of our disclosure controls and procedures (as defined in
Rule
13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation,
our chief executive officer and chief financial officer concluded that our
disclosure controls and procedures are effective to ensure that all information
required to be disclosed by us in the reports that we file or submit under
the
Exchange Act is: (1)
accumulated and communicated to our management, including our chief executive
officer and chief financial officer, as appropriate to allow timely decisions
regarding required disclosure;
and (2)
recorded, processed, summarized and reported, within the time periods specified
in the Commission's rules and forms. There was no change in our internal
controls or in other factors that could affect these controls during our last
fiscal quarter that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.
PART
II - OTHER INFORMATION
Item
1. Legal Proceedings.
As
of the
date this report was filed, there have been no material developments in the
legal proceedings previously reported in our annual report on Form 10-K for
the
fiscal year ended December 31, 2006, which was filed with the Securities and
Exchange Commission on May 16, 2007.
Item
1A. Risk Factors.
There
have been no material changes from risk factors previously disclosed in
Item 1A included in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2006, which was filed with the SEC on May 16, 2007.
Item
2. Unregistered Sales of Equity Securities and Use of
Proceeds.
Between
January 1, 2007 and April 6, 2007, the Company issued 79,138 shares of Common
Stock to various employees, directors, consultants and creditors. The Common
Stock was issued for services and payment of accrued interest. The Common Stock
was valued at approximately $131,000. These shares were issued in reliance
upon
the exemption provided by Section 4(2) of the Securities Act.
On
January 29, 2007, the Company entered into a subscription agreement and sold
an
aggregate of 800,000 shares of its Common Stock and warrants to purchase an
aggregate of up to 300,000 shares of its Common Stock in a private placement
transaction to A Plus, an accredited investor. The warrants are exercisable
for
a period of five years, have an exercise price equal to $2.00, and 50% of the
warrants are callable upon the occurrence of any one of a number of specified
events when, after any such specified occurrence, the average closing price
of
the Company’s common stock during any period of five consecutive trading days
exceeds $4.00 per share. The Company received gross proceeds of $500,000 in
cash
and will receive $500,000 in product over the course of the next twelve (12)
months. These securities were sold in reliance upon the exemption provided
by
Section 4(2) of the Securities Act and the safe harbor of Rule 506 under
Regulation D promulgated under the Securities Act. No advertising or general
solicitation was employed in offering the securities, the sales were made to
a
limited number of persons, all of whom represented to the Company that they
are
accredited investors, and transfer of the securities is restricted in accordance
with the requirements of the Securities Act.
On
January 29, 2007, the Company entered into a subscription agreement with several
unaffiliated accredited investors in a private placement exempt from the
registration requirements of the Securities Act. The Company issued and sold
to
these accredited investors an aggregate of 104,000 shares of its common stock
and warrants to purchase an additional 52,000 shares of its common stock. The
warrants are exercisable for a period of five years, have an exercise price
equal to $2.00, and 50% of the warrants are callable upon the occurrence of
any
one of a number of specified events when, after any such specified occurrence,
the average closing price of the Company’s common stock during any period of
five consecutive trading days exceeds $4.00 per share. These issuances resulted
in aggregate gross proceeds to the Company of $130,000. These securities were
sold in reliance upon the exemption provided by Section 4(2) of the Securities
Act and the safe harbor of Rule 506 under Regulation D promulgated under the
Securities Act. No advertising or general solicitation was employed in offering
the securities, the sales were made to a limited number of persons, all of
whom
represented to the Company that they are accredited investors, and transfer
of
the securities is restricted in accordance with the requirements of the
Securities Act.
On
January 30, 2007, the Company issued 8,320 warrants to purchase shares of common
stock at $2.00 per share to the Company’s Placement Agent. The warrants vested
immediately and have a five-year life. The warrants were valued at approximately
$8,000 and were expensed at the time of issuance. These securities will be
issued pursuant to Section 4(2) of the Securities Act of 1933. These warrants
were issued in reliance upon the exemption provided by Section 4(2) of the
Securities Act.
Between
March 7, 2007 and April 5, 2007, the Company entered into a subscription
agreement with several accredited investors in a private placement exempt from
the registration requirements of the Securities Act. The Company issued and
sold
to these accredited investors an aggregate of 2,000,000 shares of its common
stock and warrants to purchase an additional 1,000,000 shares of its common
stock. The warrants are exercisable for a period of five years, have an exercise
price equal to $2.00, and 50% of the warrants are callable upon the occurrence
of any one of a number of specified events when, after any such specified
occurrence, the average closing price of the Company’s common stock during any
period of five consecutive trading days exceeds $4.00 per share. These issuances
resulted in aggregate gross proceeds to the Company of $2,500,000. We are
required to use our reasonable best efforts to cause the registration statement
to become effective within 120 days after the Closing Date, April 5, 2007.
If
the registration statement has not been filed on or prior to the 120th day
after
the Closing Date, we will issue, as liquidated damages, to the purchasers of
the
2,000,000 shares of our Common Stock and the warrants to purchase 1,000,000
shares of our Common Stock warrants with a term of five years and an exercise
price of $2.00 per share to purchase shares of our Common Stock equal to 2.5%
of
the number of shares of Common Stock purchased by the purchasers. We intend
to
use the net proceeds from this private placement transaction primarily for
general corporate purposes and repayment of existing liabilities. These
securities were sold in reliance upon the exemption provided by Section 4(2)
of
the Securities Act and the safe harbor of Rule 506 under Regulation D
promulgated under the Securities Act. No advertising or general solicitation
was
employed in offering the securities, the sales were made to a limited number
of
persons, all of whom represented to the Company that they are accredited
investors, and transfer of the securities is restricted in accordance with
the
requirements of the Securities Act.
On
April
5, 2007, the Company issued 89,600 warrants to purchase shares of common stock
at $2.00 per share to the Company’s Placement Agent. The warrants vested
immediately and have a five-year life. The warrants were valued at approximately
$81,000 and were expensed at the time of issuance. These securities will be
issued pursuant to Section 4(2) of the Securities Act of 1933. These warrants
were issued in reliance upon the exemption provided by Section 4(2) of the
Securities Act.
Item
3. Defaults Upon Senior Securities.
On
January 12, 2006 ASG entered into a secured promissory note with Steven J.
Caspi
in the principal amount of $1,000,000 (the “Caspi
Note”).
The
Caspi Note was due to be repaid on July 13, 2006.
On
February 8, 2006, ASG entered into a secured promissory note with Ault Glazer
Capital Partners, LLC (the “Fund”),
a
related party, in the principal amount of $687,000 (the “ASG
Note”).
The
ASG Note was due to be repaid on September 15, 2006.
From
March 7, 2006 through October 16, 2006, the Fund loaned the Company a total
of
$524,000, of which $130,000 was repaid. The outstanding balance at March 31,
2007 is $394,000. The loans were advanced to the Company pursuant to a Revolving
Line of Credit Agreement (the “Revolving
Line of Credit”)
entered
into with the Fund on March 7, 2006. Each advance under the Revolving Line
of
Credit is evidenced by a secured promissory note and a security agreement.
The
secured promissory notes issued pursuant to the Revolving Line of Credit
required repayment within 60 days from issuance and are currently in
default.
On
May 1,
2006, the Company entered into a secured promissory note with Herbert Langsam,
a
Class II Director of the Company, in the principal amount of $500,000 (the
“Langsam
Note”).
The
Langsam Note was due to be repaid on November 1, 2006.
On
November 13, 2006, the Company entered into secured promissory note with Mr.
Langsam in the principal amount of $100,000 (the “Second
Langsam Note”).
The
Second Langsam Note was due to be repaid on May 13, 2007.
The
Company is in the process of restructuring the debt that is owed to the Fund
and
Messrs. Steven J. Caspi and Herbert Langsam.
Item
4. Submission of Matters to a Vote of Security Holders.
None.
Item
5. Other Information.
None.
Item
6. Exhibits.
Exhibit
Number
|
|
Description
|
31.1*
|
|
Certification
of Chief Executive and Financial Officer required by Rule 13a-14(a)
or
Rule 15d-14(a)
|
|
|
|
32.1*
|
|
Certification
of Chief Executive and Financial Officer required by Rule 13a-14(b)
or
Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the
United
States Code
|
*
Filed
herewith.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
PATIENT
SAFETY TECHNOLOGIES, INC.
|
|
|
|
Date:
May 21, 2007
|
By: |
/s/
William B. Horne
|
|
William
B. Horne
|
|
Chief
Executive and Chief Financial Officer and
Principal
Accounting Officer
|